Transcriptional	O
targeting	O
of	O
retroviral	O
vectors	O
to	O
the	O
erythroblastic	B-cell_type
progeny	I-cell_type
of	O
transduced	B-cell_line
hematopoietic	I-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

Targeted	O
expression	O
to	O
specific	O
tissues	O
or	O
cell	O
lineages	O
is	O
a	O
necessary	O
feature	O
of	O
a	O
gene	O
therapy	O
vector	O
for	O
many	O
clinical	O
applications	O
,	O
such	O
as	O
correction	O
of	O
hemoglobinopathies	O
or	O
thalassemias	O
by	O
transplantation	O
of	O
genetically	B-cell_type
modified	I-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
.	O

We	O
developed	O
retroviral	O
vectors	O
in	O
which	O
the	O
constitutive	B-DNA
viral	I-DNA
enhancer	I-DNA
in	O
the	O
U3	B-DNA
region	I-DNA
of	O
the	O
3	B-DNA
'	I-DNA
LTR	I-DNA
is	O
replaced	O
by	O
an	O
autoregulatory	B-DNA
enhancer	I-DNA
of	O
the	O
erythroid-specific	B-DNA
GATA-1	I-DNA
transcription	I-DNA
factor	I-DNA
gene	I-DNA
.	O

The	O
replaced	B-DNA
enhancer	I-DNA
is	O
propagated	O
to	O
the	O
5	B-DNA
'	I-DNA
LTR	I-DNA
upon	O
integration	O
into	O
the	O
target	B-DNA
cell	I-DNA
genome	I-DNA
.	O

The	O
modified	O
vectors	O
were	O
used	O
to	O
transduce	O
human	B-cell_line
hematopoietic	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
cord	B-cell_type
blood-derived	I-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
stem/progenitor	I-cell_type
cells	I-cell_type
,	O
and	O
murine	B-cell_line
bone	I-cell_line
marrow	I-cell_line
repopulating	I-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

The	O
expression	O
of	O
appropriate	O
reporter	B-DNA
genes	I-DNA
(	O
triangle	B-DNA
upLNGFR	I-DNA
,	O
EGFP	B-DNA
)	O
was	O
analyzed	O
in	O
the	O
differentiated	O
progeny	O
of	O
transduced	B-cell_line
stem	I-cell_line
cells	I-cell_line
in	O
vitro	O
,	O
in	O
liquid	O
culture	O
as	O
well	O
as	O
in	O
clonogenic	O
assay	O
,	O
and	O
in	O
vivo	O
,	O
after	O
bone	O
marrow	O
transplantation	O
in	O
lethally	O
irradiated	O
mice	O
.	O

The	O
GATA-1	B-DNA
autoregulatory	I-DNA
enhancer	I-DNA
effectively	O
restricts	O
the	O
expression	O
of	O
the	O
LTR-driven	B-DNA
proviral	I-DNA
transcription	I-DNA
unit	I-DNA
to	O
the	O
erythroblastic	B-cell_type
progeny	I-cell_type
of	O
both	O
human	B-cell_type
progenitors	I-cell_type
and	O
mouse-repopulating	B-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

Packaging	O
of	O
viral	O
particles	O
,	O
integration	O
into	O
the	O
target	O
genome	O
,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	B-DNA
modification	O
.	O

Enhancer	O
replacement	O
is	O
therefore	O
an	O
effective	O
strategy	O
to	O
target	O
expression	O
of	O
a	O
retroviral	B-DNA
transgene	I-DNA
to	O
a	O
specific	O
progeny	O
of	O
transduced	B-cell_line
hematopoietic	I-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

GENE	NULL
THERAPY	NULL
Transcriptional	NULL
Targeting	NULL
of	NULL
Retroviral	NULL
Vectors	NULL
to	NULL
the	NULL
Erythroblastic	NULL
Progeny	NULL
of	NULL
Transduced	NULL
Hematopoietic	NULL
Stem	NULL
Cells	NULL
By	NULL
Alexis	NULL
Grande	NULL
,	NULL
Bianca	NULL
Piovani	NULL
,	NULL
Alessandro	NULL
Aiuti	NULL
,	NULL
Sergio	NULL
Ottolenghi	NULL
,	NULL
Fulvio	NULL
Mavilio	NULL
,	NULL
and	NULL
Giuliana	NULL
Ferrari	NULL
Targeted	NULL
expression	NULL
to	NULL
specific	NULL
tissues	NULL
or	NULL
cell	NULL
lineages	NULL
is	NULL
a	NULL
necessary	NULL
feature	NULL
of	NULL
a	NULL
gene	NULL
therapy	NULL
vector	NULL
for	NULL
many	NULL
clinical	NULL
applications	NULL
,	NULL
such	NULL
as	NULL
correction	NULL
of	NULL
hemoglobinopathies	NULL
or	NULL
thalassemias	NULL
by	NULL
transplantation	NULL
of	NULL
genetically	NULL
modified	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
.	NULL

We	NULL
developed	NULL
retroviral	NULL
vectors	NULL
in	NULL
which	NULL
the	NULL
constitutive	NULL
viral	NULL
enhancer	NULL
in	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
is	NULL
replaced	NULL
by	NULL
an	NULL
autoregulatory	NULL
enhancer	NULL
of	NULL
the	NULL
erythroid-specific	NULL
GATA-1	NULL
transcription	NULL
factor	NULL
gene	NULL
.	NULL

The	NULL
replaced	NULL
enhancer	NULL
is	NULL
propagated	NULL
to	NULL
the	NULL
5	NULL
LTR	NULL
upon	NULL
integration	NULL
into	NULL
the	NULL
target	NULL
cell	NULL
genome	NULL
.	NULL

The	NULL
modified	NULL
vectors	NULL
were	NULL
used	NULL
to	NULL
transduce	NULL
human	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
,	NULL
cord	NULL
blood-derived	NULL
CD34+*	NULL
stem/progenitor	NULL
cells	NULL
,	NULL
and	NULL
murine	NULL
bone	NULL
marrow	NULL
repopulating	NULL
stem	NULL
cells	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
appropriate	NULL
reporter	NULL
genes	NULL
(	NULL
ALNGFR	NULL
,	NULL
EGFP	NULL
)	NULL
was	NULL
analyzed	NULL
in	NULL
the	NULL
differen-	NULL
ETROVIRAL	NULL
VECTORS	NULL
are	NULL
widely	NULL
used	NULL
to	NULL
integrate	NULL
and	NULL
express	NULL
exogenous	NULL
genes	NULL
into	NULL
a	NULL
variety	NULL
of	NULL
animal	NULL
cells	NULL
and	NULL
provide	NULL
a	NULL
safe	NULL
and	NULL
relatively	NULL
efficient	NULL
gene	NULL
transfer	NULL
tool	NULL
for	NULL
human	NULL
gene	NULL
therapy	NULL
applications	NULL
.	NULL
``	NULL

''	NULL
In	NULL
some	NULL
of	NULL
these	NULL
applications	NULL
,	NULL
controlling	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
transferred	NULL
,	NULL
therapeutic	NULL
gene	NULL
at	NULL
quantitative	NULL
and	NULL
qualitative	NULL
(	NULL
tissue-	NULL
or	NULL
cell-specific	NULL
)	NULL
level	NULL
is	NULL
a	NULL
critical	NULL
,	NULL
and	NULL
often	NULL
limiting	NULL
,	NULL
factor	NULL
.	NULL

The	NULL
most	NULL
frequently	NULL
used	NULL
backbone	NULL
for	NULL
the	NULL
construction	NULL
of	NULL
retroviral	NULL
vectors	NULL
is	NULL
the	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
(	NULL
MoMLV	NULL
)	NULL
.	NULL

Transcription	NULL
from	NULL
the	NULL
MoMLV	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
viral	NULL
promoter/enhancer	NULL
elements	NULL
located	NULL
in	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
,	NULL
which	NULL
allows	NULL
constitutive	NULL
expression	NULL
of	NULL
a	NULL
transferred	NULL
gene	NULL
in	NULL
most	NULL
cell	NULL
types	NULL
.	NULL

Conversely	NULL
,	NULL
tissue-specific	NULL
or	NULL
inducible	NULL
expression	NULL
is	NULL
difficult	NULL
to	NULL
obtain	NULL
.	NULL

Although	NULL
an	NULL
independently	NULL
controlled	NULL
transcriptional	NULL
unit	NULL
can	NULL
be	NULL
transferred	NULL
and	NULL
expressed	NULL
in	NULL
the	NULL
framework	NULL
of	NULL
a	NULL
retroviral	NULL
vector	NULL
,	NULL
the	NULL
strong	NULL
activity	NULL
of	NULL
the	NULL
MoMLV	NULL
enhancer/promoter	NULL
usually	NULL
interferes	NULL
with	NULL
,	NULL
or	NULL
prevents	NULL
,	NULL
regulation	NULL
and	NULL
function	NULL
of	NULL
most	NULL
eukaryotic	NULL
cis-acting	NULL
elements	NULL
,	NULL
even	NULL
in	NULL
the	NULL
proper	NULL
cell	NULL
context	NULL
.	NULL

*	NULL
``	NULL
Alternative	NULL
designs	NULL
have	NULL
been	NULL
developed	NULL
in	NULL
an	NULL
attempt	NULL
to	NULL
overcome	NULL
this	NULL
problem	NULL
,	NULL
from	NULL
self-inactivating	NULL
vectors	NULL
,	NULL
in	NULL
which	NULL
deletion	NULL
of	NULL
viral	NULL
elements	NULL
allows	NULL
expression	NULL
from	NULL
an	NULL
internal	NULL
promoter	NULL
,	NULL
``	NULL
``	NULL
to	NULL
vectors	NULL
in	NULL
which	NULL
a	NULL
transgene	NULL
is	NULL
transcribed	NULL
in	NULL
opposite	NULL
orientation	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
viral	NULL
transcription	NULL
unit	NULL
,	NULL
``	NULL
``	NULL
to	NULL
double-copy	NULL
vectors	NULL
in	NULL
which	NULL
a	NULL
complete	NULL
minigene	NULL
is	NULL
inserted	NULL
From	NULL
TIGET	NULL
,	NULL
Istituto	NULL
Scientifico	NULL
H.S	NULL
.	NULL

Raffaele	NULL
,	NULL
Milano	NULL
,	NULL
Italy	NULL
;	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Genetics	NULL
,	NULL
University	NULL
of	NULL
Milano	NULL
,	NULL
Milano	NULL
,	NULL
Italy	NULL
.	NULL

Submitted	NULL
September	NULL
22	NULL
,	NULL
1998	NULL
;	NULL
accepted	NULL
January	NULL
13	NULL
,	NULL
1999	NULL
.	NULL

Supported	NULL
by	NULL
a	NULL
core	NULL
grant	NULL
from	NULL
the	NULL
Italian	NULL
Telethon	NULL
Foundation	NULL
and	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Istituto	NULL
Superiore	NULL
di	NULL
Sanita	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Giuliana	NULL
Ferrari	NULL
,	NULL
PhD	NULL
,	NULL
TIGET	NULL
H.S	NULL
.	NULL

Raffaele	NULL
,	NULL
Via	NULL
Olgettina	NULL
,	NULL
58	NULL
,	NULL
20132	NULL
Milano	NULL
,	NULL
Italy	NULL
;	NULL
e-mail	NULL
:	NULL
ferrari	NULL
@	NULL
tigem.it	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

Â©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/99/9310-0009	NULL
$	NULL
3.00/0	NULL
3276	NULL
tiated	NULL
progeny	NULL
of	NULL
transduced	NULL
stem	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
in	NULL
liquid	NULL
culture	NULL
as	NULL
well	NULL
as	NULL
in	NULL
clonogenic	NULL
assay	NULL
,	NULL
and	NULL
in	NULL
vivo	NULL
,	NULL
after	NULL
bone	NULL
marrow	NULL
transplantation	NULL
in	NULL
lethally	NULL
irradiated	NULL
mice	NULL
.	NULL

The	NULL
GATA-1	NULL
autoregulatory	NULL
enhancer	NULL
effectively	NULL
restricts	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
LTR-driven	NULL
proviral	NULL
transcription	NULL
unit	NULL
to	NULL
the	NULL
erythroblastic	NULL
progeny	NULL
of	NULL
both	NULL
human	NULL
progenitors	NULL
and	NULL
mouse-repopulating	NULL
stem	NULL
cells	NULL
.	NULL

Packaging	NULL
of	NULL
viral	NULL
particles	NULL
,	NULL
integration	NULL
into	NULL
the	NULL
target	NULL
genome	NULL
,	NULL
and	NULL
stability	NULL
of	NULL
the	NULL
integrated	NULL
provirus	NULL
are	NULL
not	NULL
affected	NULL
by	NULL
the	NULL
LTR	NULL
modification	NULL
.	NULL

Enhancer	NULL
replacement	NULL
is	NULL
therefore	NULL
an	NULL
effective	NULL
strategy	NULL
to	NULL
target	NULL
expression	NULL
of	NULL
a	NULL
retroviral	NULL
transgene	NULL
to	NULL
a	NULL
specific	NULL
progeny	NULL
of	NULL
transduced	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
.	NULL

Â©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

into	NULL
the	NULL
LTR	NULL
upstream	NULL
from	NULL
the	NULL
U3	NULL
region	NULL
.	NULL
``	NULL

''	NULL
These	NULL
strategies	NULL
frequently	NULL
raise	NULL
other	NULL
problems	NULL
,	NULL
such	NULL
as	NULL
generation	NULL
of	NULL
antisense	NULL
transcripts	NULL
,	NULL
proviral	NULL
instability	NULL
,	NULL
or	NULL
decreased	NULL
viral	NULL
titer	NULL
.	NULL

Attempts	NULL
to	NULL
redirect	NULL
the	NULL
promiscuous	NULL
MoMLV	NULL
LTR	NULL
transcriptional	NULL
activity	NULL
by	NULL
adding	NULL
to	NULL
or	NULL
replacing	NULL
the	NULL
viral	NULL
enhancer	NULL
with	NULL
heterologous	NULL
control	NULL
elements	NULL
from	NULL
other	NULL
viruses	NULL
or	NULL
cellular	NULL
genes	NULL
have	NULL
been	NULL
partially	NULL
successful	NULL
,	NULL
allowing	NULL
investigators	NULL
to	NULL
change	NULL
the	NULL
vector	NULL
tropism	NULL
!	NULL

or	NULL
increase	NULL
transgene	NULL
expression	NULL
in	NULL
specific	NULL
tissues	NULL
``	NULL
or	NULL
cell	NULL
contexts	NULL
.	NULL

!	NULL

*	NULL
For	NULL
correction	NULL
of	NULL
genetic	NULL
disorders	NULL
such	NULL
as	NULL
hemoglobinopathies	NULL
or	NULL
thalassemias	NULL
,	NULL
in	NULL
which	NULL
the	NULL
ultimate	NULL
goal	NULL
is	NULL
to	NULL
restrict	NULL
transgene	NULL
expression	NULL
to	NULL
a	NULL
specific	NULL
progeny-the	NULL
erythropoietic	NULL
compartment-of	NULL
the	NULL
hematopoietic	NULL
stem	NULL
cell	NULL
,	NULL
transcriptional	NULL
targeting	NULL
of	NULL
the	NULL
vector	NULL
is	NULL
a	NULL
mandatory	NULL
requirement	NULL
.	NULL

We	NULL
report	NULL
the	NULL
development	NULL
of	NULL
targeted	NULL
retroviral	NULL
vectors	NULL
obtained	NULL
by	NULL
replacing	NULL
the	NULL
LTR	NULL
extended	NULL
viral	NULL
enhancer	NULL
with	NULL
an	NULL
autoregulatory	NULL
enhancer	NULL
(	NULL
ARE	NULL
)	NULL
of	NULL
the	NULL
erythroid-specific	NULL
,	NULL
zinc	NULL
finger	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
.	NULL
'	NULL

5	NULL
``	NULL
*	NULL
The	NULL
GATA-1	NULL
ARE	NULL
is	NULL
a	NULL
200-bp	NULL
,	NULL
conserved	NULL
element	NULL
upstream	NULL
of	NULL
the	NULL
GATA-1	NULL
erythroid-specific	NULL
promoter	NULL
(	NULL
-856	NULL
to	NULL
-655	NULL
)	NULL
and	NULL
contains	NULL
two	NULL
palyndromic	NULL
GATA-1	NULL
binding	NULL
sites	NULL
.	NULL

This	NULL
element	NULL
was	NULL
previously	NULL
shown	NULL
to	NULL
restrict	NULL
transcription	NULL
of	NULL
a	NULL
heterologous	NULL
promoter	NULL
to	NULL
human	NULL
or	NULL
murine	NULL
erythroblastic	NULL
cell	NULL
lines	NULL
in	NULL
transient	NULL
transfection	NULL
.	NULL
``	NULL

The	NULL
LTR	NULL
modification	NULL
was	NULL
introduced	NULL
in	NULL
retroviral	NULL
vectors	NULL
encoding	NULL
either	NULL
a	NULL
truncated	NULL
form	NULL
of	NULL
the	NULL
human	NULL
p75	NULL
,	NULL
low-affinity	NULL
nerve	NULL
growth	NULL
factor	NULL
receptor	NULL
(	NULL
ALNGFR	NULL
)	NULL
,	NULL
or	NULL
a	NULL
humanized	NULL
form	NULL
of	NULL
the	NULL
green	NULL
fluorescent	NULL
protein	NULL
(	NULL
EGFP	NULL
)	NULL
to	NULL
allow	NULL
detection	NULL
of	NULL
transgene	NULL
expression	NULL
with	NULL
single-cell	NULL
resolution	NULL
by	NULL
flow	NULL
cytometry	NULL
!	NULL
``	NULL

or	NULL
in	NULL
situ	NULL
in	NULL
a	NULL
colony-forming	NULL
assay	NULL
.	NULL

Human	NULL
cord	NULL
blood-derived	NULL
hematopoietic	NULL
stem/progenitor	NULL
cells	NULL
,	NULL
including	NULL
the	NULL
CD34*/	NULL
CD38	NULL
``	NULL
fraction	NULL
,	NULL
and	NULL
mouse	NULL
repopulating	NULL
bone	NULL
marrow	NULL
(	NULL
BM	NULL
)	NULL
stem	NULL
cells	NULL
were	NULL
transduced	NULL
by	NULL
the	NULL
modified	NULL
vectors	NULL
and	NULL
analyzed	NULL
for	NULL
transgene	NULL
expression	NULL
in	NULL
the	NULL
differentiated	NULL
prog-enies	NULL
in	NULL
vitro	NULL
or	NULL
after	NULL
BM	NULL
transplantation	NULL
ex	NULL
vivo	NULL
.	NULL

We	NULL
show	NULL
that	NULL
enhancer	NULL
replacement	NULL
does	NULL
not	NULL
affect	NULL
transduction	NULL
and	NULL
stability	NULL
of	NULL
the	NULL
retroviral	NULL
vectors	NULL
and	NULL
effectively	NULL
restricts	NULL
LTR-driven	NULL
expression	NULL
to	NULL
the	NULL
erythropoietic	NULL
progeny	NULL
of	NULL
transduced	NULL
stem	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
93	NULL
,	NULL
No	NULL
10	NULL
(	NULL
May	NULL
15	NULL
)	NULL
,	NULL
1999	NULL
:	NULL
pp	NULL
3276-3285	NULL
TRANSCRIPTIONAL	NULL
TARGETING	NULL
OF	NULL
RETROVIRAL	NULL
VECTORS	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Retroviral	NULL
vectors	NULL
and	NULL
producer	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
SECM	NULL
retroviral	NULL
vector	NULL
,	NULL
encoding	NULL
the	NULL
ALNGFR	NULL
cDNA	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
viral	NULL
LTR	NULL
,	NULL
was	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

''	NULL
The	NULL
ASFCM	NULL
vector	NULL
was	NULL
derived	NULL
by	NULL
replacing	NULL
the	NULL
enhancer	NULL
and	NULL
CAAT	NULL
box	NULL
in	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
,	NULL
from	NULL
the	NULL
Nhe	NULL
I	NULL
site	NULL
to	NULL
position	NULL
-60	NULL
from	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
,	NULL
with	NULL
a	NULL
23-bp	NULL
polylinker	NULL
.	NULL

The	NULL
GATA-SFCM	NULL
vector	NULL
was	NULL
obtained	NULL
by	NULL
cloning	NULL
the	NULL
0.2-kb	NULL
BamHI	NULL
fragment	NULL
of	NULL
the	NULL
pSVOGATA	NULL
plasmid'Â®	NULL
containing	NULL
the	NULL
GATA-1	NULL
ARE	NULL
in	NULL
the	NULL
SnaBI	NULL
site	NULL
of	NULL
the	NULL
ASFCM	NULL
LTR	NULL
polylinker	NULL
.	NULL

The	NULL
LGSN	NULL
vector	NULL
was	NULL
constructed	NULL
by	NULL
cloning	NULL
the	NULL
Eco47IIW/Sca	NULL
I	NULL
fragment	NULL
of	NULL
the	NULL
pEGFP-C3	NULL
plasmid	NULL
(	NULL
Clontech	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
containing	NULL
the	NULL
EGFP	NULL
gene	NULL
in	NULL
the	NULL
Hpa	NULL
I	NULL
site	NULL
of	NULL
the	NULL
LXSN	NULL
vector	NULL
.	NULL
``	NULL

The	NULL
GATA-LGSN	NULL
vector	NULL
was	NULL
obtained	NULL
by	NULL
replacing	NULL
the	NULL
ALNGFR	NULL
insert	NULL
of	NULL
GATA-SFCM	NULL
with	NULL
the	NULL
EGFP	NULL
insert	NULL
of	NULL
LGSN	NULL
.	NULL

Packaging	NULL
lines	NULL
for	NULL
LGSN	NULL
and	NULL
SFCM	NULL
were	NULL
generated	NULL
by	NULL
transinfec-tion	NULL
in	NULL
the	NULL
amphotropic	NULL
and	NULL
ecotropic	NULL
GP+E-86	NULL
cells	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
,	NULL
``	NULL
``	NULL
whereas	NULL
those	NULL
for	NULL
ASFCM	NULL
,	NULL
GATA-SFCM	NULL
,	NULL
and	NULL
GATA-LGSN	NULL
were	NULL
obtained	NULL
by	NULL
plasmid	NULL
transfection	NULL
and	NULL
selection	NULL
in	NULL
0.8	NULL
mg/mL	NULL
G418	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Viral	NULL
titers	NULL
were	NULL
assayed	NULL
by	NULL
transfer	NULL
of	NULL
G418	NULL
resistance	NULL
to	NULL
NIH-3T3	NULL
fibroblasts	NULL
.	NULL

Transduction	NULL
of	NULL
hematopoietic	NULL
cells	NULL
.	NULL

-	NULL
Mouse	NULL
erythroleukemia	NULL
(	NULL
MEL	NULL
)	NULL
cells	NULL
were	NULL
transduced	NULL
as	NULL
described	NULL
.	NULL

``	NULL
*	NULL
Human	NULL
hematopoietic	NULL
K562	NULL
,	NULL
Kasumi-1	NULL
,	NULL
U937	NULL
,	NULL
and	NULL
MOLT-3	NULL
cell	NULL
lines	NULL
(	NULL
ATCC	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
,	NULL
transduced	NULL
by	NULL
48	NULL
hours	NULL
of	NULL
cocultivation	NULL
with	NULL
irradiated	NULL
(	NULL
100	NULL
Gy	NULL
)	NULL
packaging	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
polybrene	NULL
(	NULL
8	NULL
ug/mL	NULL
)	NULL
,	NULL
and	NULL
selected	NULL
as	NULL
bulk	NULL
cultures	NULL
in	NULL
1.0	NULL
to	NULL
1.5	NULL
mg/mL	NULL
of	NULL
G418	NULL
.	NULL

Human	NULL
CD34*	NULL
cells	NULL
were	NULL
purified	NULL
from	NULL
the	NULL
Ficoll	NULL
(	NULL
Lymphoprep	NULL
;	NULL
Nycomed	NULL
Pharma	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
)	NULL
mononuclear	NULL
cell	NULL
fraction	NULL
of	NULL
umbilical	NULL
cord	NULL
blood	NULL
by	NULL
a	NULL
two-round	NULL
separation	NULL
procedure	NULL
using	NULL
the	NULL
CD34	NULL
magnetic	NULL
cell	NULL
isolation	NULL
kit	NULL
(	NULL
MiniMacs	NULL
;	NULL
Miltenyi	NULL
,	NULL
Auburn	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

CD34	NULL
*	NULL
cells	NULL
(	NULL
5	NULL
to	NULL
10	NULL
X	NULL
10	NULL
%	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
Iscove	NULL
's	NULL
modified	NULL
Dulbecco	NULL
's	NULL
medium	NULL
(	NULL
IMDM	NULL
;	NULL
GIBCO	NULL
)	NULL
containing	NULL
20	NULL
%	NULL
FCS	NULL
,	NULL
10	NULL
ng/mL	NULL
human	NULL
interleukin-3	NULL
(	NULL
buIL-3	NULL
)	NULL
,	NULL
hulL-6	NULL
,	NULL
and	NULL
human	NULL
stem	NULL
cell	NULL
factor	NULL
(	NULL
huSCF	NULL
;	NULL
all	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
for	NULL
48	NULL
hours	NULL
and	NULL
transduced	NULL
by	NULL
multiple	NULL
cycles	NULL
of	NULL
infection	NULL
with	NULL
retroviral	NULL
supernatant	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
polybrene	NULL
(	NULL
4	NULL
ug/mL	NULL
)	NULL
.	NULL

Transduction	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
upper	NULL
chamber	NULL
of	NULL
Transwell	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
coculture	NULL
plates	NULL
above	NULL
the	NULL
murine	NULL
,	NULL
clonal	NULL
stromal	NULL
cell	NULL
line	NULL
CBR-BM	NULL
,	NULL
D	NULL
#	NULL
1	NULL
.	NULL

*	NULL
Cells	NULL
were	NULL
then	NULL
cultured	NULL
for	NULL
an	NULL
additional	NULL
48	NULL
hours	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
4	NULL
U/mL	NULL
human	NULL
erythropoietin	NULL
(	NULL
huEpo	NULL
;	NULL
Janssen-Cilag	NULL
,	NULL
Geel	NULL
,	NULL
Belgium	NULL
}	NULL
.	NULL

Transduced	NULL
CD34	NULL
*	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
liquid	NULL
culture	NULL
in	NULL
X-VIVO	NULL
20	NULL
serum-free	NULL
medium	NULL
(	NULL
Biowhittaker	NULL
,	NULL
Walkersville	NULL
,	NULL
MD	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
ng/mL	NULL
huSCF	NULL
and	NULL
4	NULL
U/mL	NULL
huEpo	NULL
to	NULL
induce	NULL
erythroid	NULL
differentiation	NULL
or	NULL
were	NULL
grown	NULL
in	NULL
IMDM	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
10	NULL
ng/mL	NULL
huSCF	NULL
,	NULL
hulL-6	NULL
,	NULL
hulL-3	NULL
,	NULL
and	NULL
human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
to	NULL
induce	NULL
myeloid	NULL
differentiation	NULL
and	NULL
were	NULL
then	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Colony-forming	NULL
assay	NULL
was	NULL
performed	NULL
by	NULL
plating	NULL
5	NULL
to	NULL
10	NULL
X	NULL
10Â°	NULL
transduced	NULL
CD34	NULL
*	NULL
cells	NULL
in	NULL
1	NULL
mL	NULL
of	NULL
methylcellulose	NULL
culture	NULL
medium	NULL
(	NULL
Stem	NULL
Cell	NULL
Technologies	NULL
,	NULL
Vancou-ver	NULL
,	NULL
British	NULL
Columbia	NULL
,	NULL
Canada	NULL
)	NULL
containing	NULL
50	NULL
ng/mL	NULL
huSCF	NULL
,	NULL
10	NULL
ng/mL	NULL
huGM-CSF	NULL
,	NULL
10	NULL
ng/mL	NULL
hullL-3	NULL
,	NULL
3	NULL
U/mL	NULL
huEpo	NULL
,	NULL
and	NULL
1.2	NULL
to	NULL
1.8	NULL
mg/mL	NULL
G418	NULL
.	NULL

Burst-forming	NULL
unit-erythroid	NULL
(	NULL
BFU-E	NULL
)	NULL
and	NULL
colony-forming	NULL
unit-granulocyte-macrophage	NULL
(	NULL
CFU-GM	NULL
)	NULL
colonies	NULL
were	NULL
scored	NULL
10	NULL
to	NULL
14	NULL
days	NULL
after	NULL
plating	NULL
,	NULL
harvested	NULL
,	NULL
and	NULL
analyzed	NULL
for	NULL
ALNGFR	NULL
expression	NULL
by	NULL
immunocytochemistry	NULL
.	NULL

Analysis	NULL
of	NULL
transduced	NULL
cells	NULL
.	NULL

|	NULL
Expression	NULL
of	NULL
ALNGFR	NULL
was	NULL
monitored	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
FACScan	NULL
;	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
the	NULL
murine	NULL
antihuman	NULL
p75-NGFR	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MoAb	NULL
)	NULL
20.4	NULL
(	NULL
ATCC	NULL
)	NULL
,	NULL
conjugated	NULL
to	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
.	NULL

Human	NULL
cell	NULL
surface	NULL
phenotype	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
-conjugated	NULL
antihuman	NULL
CD34	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
,	NULL
3277	NULL
Glycophorin	NULL
A	NULL
(	NULL
GpAÂ¥	NULL
)	NULL
and	NULL
CD13	NULL
(	NULL
DAKO	NULL
A/S	NULL
,	NULL
Glostrup	NULL
,	NULL
Denmark	NULL
)	NULL
,	NULL
and	NULL
tricolor	NULL
(	NULL
TC	NULL
)	NULL
-conjugated	NULL
antihuman	NULL
CD38	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
MoAbs	NULL
.	NULL

Mouse	NULL
cell	NULL
phenotyping	NULL
was	NULL
performed	NULL
using	NULL
PE-conjugated	NULL
antimouse	NULL
Sca-1	NULL
,	NULL
TER-119	NULL
,	NULL
and	NULL
Gr-1	NULL
(	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
antibodies	NULL
.	NULL

The	NULL
FITC-conjugated	NULL
,	NULL
antimouse	NULL
CD45.1	NULL
MoAb	NULL
(	NULL
PharMingen	NULL
)	NULL
was	NULL
used	NULL
to	NULL
evaluate	NULL
donor-host	NULL
chimerism	NULL
in	NULL
BM-transplanted	NULL
mice	NULL
.	NULL

Isotype-matched	NULL
nonspecific	NULL
antibodies	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
.	NULL

Cyto-centrifuged	NULL
cell	NULL
preparations	NULL
were	NULL
acetone-fixed	NULL
and	NULL
analyzed	NULL
for	NULL
ALNGFR	NULL
expression	NULL
by	NULL
immunocytochemistry	NULL
with	NULL
alkaline	NULL
phosphatase	NULL
antialkaline	NULL
phosphatase	NULL
(	NULL
APAAP	NULL
)	NULL
complex	NULL
following	NULL
standard	NULL
methods	NULL
.	NULL

Samples	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
hour	NULL
with	NULL
20.4	NULL
MoAb	NULL
(	NULL
1:50	NULL
dilution	NULL
)	NULL
,	NULL
washed	NULL
,	NULL
incubated	NULL
for	NULL
30	NULL
minutes	NULL
with	NULL
rabbit	NULL
antimouse	NULL
IgG	NULL
(	NULL
DAKO	NULL
A/S	NULL
;	NULL
1:25	NULL
dilution	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
APAAP	NULL
complex	NULL
(	NULL
DAKO	NULL
A/S	NULL
;	NULL
1:50	NULL
dilution	NULL
)	NULL
for	NULL
an	NULL
additional	NULL
30	NULL
minutes	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
developed	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
,	NULL
pH	NULL
8.2	NULL
,	NULL
containing	NULL
Naphtol	NULL
AS-MX	NULL
,	NULL
Fast	NULL
Red	NULL
TR	NULL
salt	NULL
,	NULL
and	NULL
levamisole	NULL
(	NULL
all	NULL
from	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Slides	NULL
were	NULL
counterstained	NULL
with	NULL
hematoxylin	NULL
before	NULL
analysis	NULL
.	NULL

RNA	NULL
analysis	NULL
.	NULL

Total	NULL
cellular	NULL
RNA	NULL
was	NULL
extracted	NULL
by	NULL
guanidine-isothiocyanate	NULL
,	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
selected	NULL
by	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-cellulose	NULL
chromatogra-phy	NULL
,	NULL
size-fractionated	NULL
on	NULL
1	NULL
%	NULL
agarose-formaldeyde	NULL
gel	NULL
,	NULL
Northern	NULL
blotted	NULL
to	NULL
nylon	NULL
membranes	NULL
,	NULL
and	NULL
hybridized	NULL
to	NULL
10	NULL
``	NULL
dpm	NULL
of	NULL
probes	NULL
for	NULL
the	NULL
neomycin	NULL
phosphotransferase	NULL
(	NULL
NeoR	NULL
)	NULL
,	NULL
GATA-1	NULL
,	NULL
*	NULL
``	NULL
and	NULL
glyceral-dehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
genes	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Transduction	NULL
of	NULL
murine	NULL
BM	NULL
and	NULL
BM	NULL
transplantation	NULL
.	NULL

-	NULL
Murine	NULL
BM	NULL
cells	NULL
were	NULL
harvested	NULL
from	NULL
C57B1/6-Ly-5.1	NULL
mice	NULL
(	NULL
B/6.SJL-CD45*-Pep*	NULL
;	NULL
Jackson	NULL
Laboratories	NULL
,	NULL
Bar	NULL
Harbor	NULL
,	NULL
ME	NULL
)	NULL
by	NULL
flushing	NULL
femurs	NULL
and	NULL
tibiae	NULL
;	NULL
prestimulated	NULL
for	NULL
24	NULL
hours	NULL
in	NULL
IMDM	NULL
supplemented	NULL
with	NULL
20	NULL
%	NULL
FCS	NULL
,	NULL
10	NULL
ng/mL	NULL
muSCF	NULL
,	NULL
muIL-3	NULL
,	NULL
and	NULL
hullL-6	NULL
(	NULL
all	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
;	NULL
and	NULL
infected	NULL
by	NULL
coculture	NULL
for	NULL
72	NULL
hours	NULL
with	NULL
irradiated	NULL
(	NULL
100	NULL
Gy	NULL
)	NULL
ecotropic	NULL
packaging	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
polybrene	NULL
(	NULL
4	NULL
ug/mL	NULL
)	NULL
.	NULL

Transduced	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
efficiency	NULL
of	NULL
gene	NULL
transfer	NULL
by	NULL
flow	NULL
cytometry	NULL
and	NULL
injected	NULL
(	NULL
1.0	NULL
to	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
cells/mouse	NULL
)	NULL
into	NULL
the	NULL
tail	NULL
vein	NULL
of	NULL
recipient	NULL
8-to	NULL
12-week-old	NULL
male	NULL
C57BL/6	NULL
mice	NULL
(	NULL
Charles	NULL
River	NULL
,	NULL
Calco	NULL
,	NULL
Italy	NULL
)	NULL
irradiated	NULL
with	NULL
two	NULL
split	NULL
doses	NULL
of	NULL
400	NULL
cGy	NULL
4	NULL
hours	NULL
apart	NULL
.	NULL

Eight	NULL
weeks	NULL
after	NULL
BM	NULL
transplantation	NULL
,	NULL
animals	NULL
were	NULL
killed	NULL
and	NULL
hematopoietic	NULL
tissues	NULL
were	NULL
collected	NULL
for	NULL
FACS	NULL
and	NULL
immunocytochemical	NULL
analysis	NULL
.	NULL

RESULTS	NULL
Targeting	NULL
retroviral	NULL
vectors	NULL
by	NULL
LTR	NULL
enhancer	NULL
replacement	NULL
.	NULL

The	NULL
GATA-1	NULL
ARE	NULL
was	NULL
inserted	NULL
in	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
of	NULL
the	NULL
previously	NULL
described	NULL
SFCM	NULL
vector	NULL
,	NULL
``	NULL
``	NULL
in	NULL
which	NULL
the	NULL
cDNA	NULL
for	NULL
the	NULL
marker	NULL
gene	NULL
ALNGFR	NULL
and	NULL
a	NULL
NeoR	NULL
gene	NULL
are	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
viral	NULL
LTR	NULL
and	NULL
of	NULL
an	NULL
internal	NULL
SV40	NULL
promoter	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

The	NULL
modification	NULL
is	NULL
transferred	NULL
to	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
upon	NULL
reverse	NULL
transcription	NULL
and	NULL
integration	NULL
of	NULL
the	NULL
provirus	NULL
,	NULL
allowing	NULL
the	NULL
chimeric	NULL
LTR	NULL
to	NULL
direct	NULL
transcription	NULL
of	NULL
the	NULL
ALNGFR	NULL
transgene	NULL
.	NULL

We	NULL
first	NULL
replaced	NULL
the	NULL
LTR	NULL
enhancer	NULL
direct	NULL
repeats	NULL
(	NULL
from	NULL
position	NULL
-419	NULL
to	NULL
-149	NULL
from	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
)	NULL
with	NULL
the	NULL
GATA-1	NULL
ARE	NULL
.	NULL

The	NULL
residual	NULL
activity	NULL
of	NULL
this	NULL
partially	NULL
deleted	NULL
LTR	NULL
was	NULL
still	NULL
constitutively	NULL
high	NULL
in	NULL
all	NULL
tested	NULL
cells	NULL
,	NULL
although	NULL
reduced	NULL
approximately	NULL
fivefold	NULL
as	NULL
compared	NULL
with	NULL
a	NULL
wild-type	NULL
LTR	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
generated	NULL
the	NULL
ASFCM	NULL
vector	NULL
by	NULL
deleting	NULL
the	NULL
viral	NULL
enhancer	NULL
and	NULL
CAAT	NULL
box	NULL
(	NULL
from	NULL
position	NULL
-419	NULL
to	NULL
-60	NULL
)	NULL
,	NULL
leaving	NULL
intact	NULL
only	NULL
the	NULL
TATA	NULL
and	NULL
initiator	NULL
elements	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

The	NULL
GATA-SFCM	NULL
vector	NULL
was	NULL
constructed	NULL
by	NULL
cloning	NULL
the	NULL
GATA-1	NULL
ARE	NULL
in	NULL
the	NULL
LTR	NULL
of	NULL
ASFCM	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

Retroviral	NULL
vectors	NULL
containing	NULL
the	NULL
EGFP	NULL
gene	NULL
as	NULL
an	NULL
alternative	NULL
reporter	NULL
(	NULL
LGSN	NULL
and	NULL
GATA-LGSN	NULL
)	NULL
were	NULL
built	NULL
3278	NULL
MOLT-3	NULL
A	NULL
-G	NULL
S	NULL
A	NULL
-G	NULL
Ss	NULL
GATA-1	NULL
..	NULL
â	NULL
.	NULL

``	NULL
|	NULL
3T3	NULL
GRANDE	NULL
ET	NULL
AL	NULL
c	NULL
WWA	NULL
HHH	NULL
Fig	NULL
1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
transcripts	NULL
from	NULL
K562	NULL
(	NULL
erythroblastic	NULL
)	NULL
,	NULL
3T3	NULL
(	NULL
fibroblas-tic	NULL
)	NULL
,	NULL
MOLT-3	NULL
(	NULL
T-lymphocytic	NULL
)	NULL
,	NULL
and	NULL
(	NULL
A	NULL
)	NULL
n	NULL
Kasumi-1	NULL
(	NULL
myeloblastic	NULL
)	NULL
cell	NULL
lines	NULL
transduced	NULL
with	NULL
ASFCM	NULL
(	NULL
lanes	NULL
[	NULL
*	NULL
|	NULL
ALNGFR	NULL
__|-	NULL
[	NULL
SV	NULL
|	NULL
_NeoR	NULL
__|-|	NULL
LTR	NULL
|	NULL
A	NULL
)	NULL
,	NULL
GATA-SFCM	NULL
(	NULL
lanes	NULL
G	NULL
)	NULL
,	NULL
and	NULL
SFCM	NULL
(	NULL
lanes	NULL
S	NULL
)	NULL
retroviral	NULL
vec-	NULL
*	NULL
R	NULL
|	NULL
LT	NULL
I	NULL
~-	NULL
1	NULL
TATA\\~	NULL
GATT	NULL
[	NULL
_|	NULL
MoMLV-E	NULL
R	NULL
_|	NULL
US	NULL
|	NULL
TATA	NULL
n	NULL
[	NULL
us	NULL
]	NULL
TATA	NULL
P	NULL
,	NULL
|	NULL
|	NULL
Gatai-e	NULL
|	NULL
R	NULL
|	NULL
us	NULL
)	NULL
following	NULL
the	NULL
same	NULL
strategy	NULL
.	NULL

Amphotropic	NULL
and	NULL
ecotropic	NULL
producer	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
by	NULL
transfecting	NULL
hybrid-LTR	NULL
plasmid	NULL
vectors	NULL
and	NULL
isolating	NULL
G418-resistant	NULL
clones	NULL
.	NULL

Efficiency	NULL
of	NULL
gene	NULL
transfer	NULL
was	NULL
assayed	NULL
by	NULL
infecting	NULL
GATA-1-expressing	NULL
cell	NULL
lines	NULL
(	NULL
human	NULL
K562	NULL
for	NULL
amphotropic	NULL
and	NULL
MEL	NULL
cells	NULL
for	NULL
ecotropic	NULL
vectors	NULL
)	NULL
and	NULL
counting	NULL
ALNGFR*	NULL
or	NULL
EGFP+*	NULL
cells	NULL
by	NULL
FACS	NULL
analysis	NULL
48	NULL
hours	NULL
after	NULL
infection	NULL
.	NULL

Positive	NULL
cells	NULL
SFCM	NULL
ASFCM	NULL
GATA-SFCM	NULL
(	NULL
G	NULL
)	NULL
tors	NULL
,	NULL
after	NULL
hybridization	NULL
to	NULL
NeoR	NULL
(	NULL
upper	NULL
panels	NULL
)	NULL
,	NULL
GATA-1	NULL
(	NULL
middle	NULL
panels	NULL
)	NULL
,	NULL
or	NULL
GAPDH	NULL
(	NULL
lower	NULL
panels	NULL
)	NULL
probes	NULL
.	NULL

Transcripts	NULL
from	NULL
the	NULL
viral	NULL
LTR	NULL
(	NULL
LTR	NULL
)	NULL
or	NULL
the	NULL
internal	NULL
SV40	NULL
(	NULL
SV	NULL
)	NULL
promoters	NULL
are	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
SFCM	NULL
retroviral	NULL
provirus	NULL
and	NULL
5	NULL
'	NULL
LTR	NULL
and	NULL
of	NULL
the	NULL
modified	NULL
5Â°	NULL
LTRs	NULL
of	NULL
the	NULL
ASFCM	NULL
and	NULL
GATA-SFCM	NULL
vectors	NULL
.	NULL

LTR	NULL
and	NULL
SV40	NULL
promoters	NULL
are	NULL
indicated	NULL
by	NULL
arrow	NULL
s.	NULL
(	NULL
A	NULL
)	NULL
``	NULL
indicates	NULL
the	NULL
polyadenylation	NULL
site	NULL
.	NULL

The	NULL
LTR	NULL
U3	NULL
wild-type	NULL
enhancer	NULL
(	NULL
MoM	NULL
LV-E	NULL
)	NULL
,	NULL
the	NULL
GATA-1	NULL
enhancer	NULL
(	NULL
GATA1-E	NULL
)	NULL
,	NULL
the	NULL
LTR	NULL
R	NULL
and	NULL
US	NULL
regions	NULL
,	NULL
and	NULL
the	NULL
CAAT	NULL
and	NULL
TATA	NULL
elements	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
S	NULL
)	NULL
(	NULL
A	NULL
)	NULL
ranged	NULL
from	NULL
5	NULL
%	NULL
to	NULL
25	NULL
%	NULL
in	NULL
cultures	NULL
transduced	NULL
by	NULL
enhancer-replaced	NULL
LTR	NULL
vectors	NULL
and	NULL
from	NULL
50	NULL
%	NULL
to	NULL
80	NULL
%	NULL
in	NULL
cultures	NULL
transduced	NULL
by	NULL
wild-type	NULL
LTR	NULL
vectors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
differences	NULL
correlated	NULL
with	NULL
the	NULL
viral	NULL
titers	NULL
assayed	NULL
on	NULL
NIH/3T3	NULL
cells	NULL
,	NULL
which	NULL
ranged	NULL
from	NULL
10	NULL
%	NULL
to	NULL
10Â°	NULL
cfu/mL	NULL
for	NULL
ASFCM	NULL
,	NULL
GATA-SFCM	NULL
,	NULL
and	NULL
GATA-LGSN	NULL
vectors	NULL
to	NULL
10Â°	NULL
cfu/ml	NULL
for	NULL
SFCM	NULL
and	NULL
LGSN	NULL
vectors	NULL
.	NULL

TRANSCRIPTIONAL	NULL
TARGETING	NULL
OF	NULL
RETROVIRAL	NULL
VECTORS	NULL
The	NULL
GATA-SFCM	NULL
vector	NULL
is	NULL
expressed	NULL
only	NULL
in	NULL
erythroblastic	NULL
The	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
chimeric	NULL
LTR	NULL
was	NULL
tested	NULL
in	NULL
different	NULL
cell	NULL
lines	NULL
of	NULL
hemato-lymphopoietic	NULL
origin	NULL
.	NULL

Human	NULL
myeloblastic	NULL
(	NULL
Kasumi-1	NULL
)	NULL
,	NULL
monoblastic	NULL
(	NULL
U937	NULL
)	NULL
,	NULL
erythroblastic	NULL
(	NULL
K562	NULL
)	NULL
,	NULL
and	NULL
T-lymphoblastic	NULL
(	NULL
MOLT-3	NULL
)	NULL
cell	NULL
lines	NULL
and	NULL
murine	NULL
erythroblastic	NULL
(	NULL
MEL	NULL
)	NULL
and	NULL
fibroblasts	NULL
(	NULL
NIH	NULL
3T3	NULL
)	NULL
cells	NULL
were	NULL
transduced	NULL
with	NULL
the	NULL
SFCM	NULL
,	NULL
ASFCM	NULL
,	NULL
and	NULL
GATA-SFCM	NULL
retroviral	NULL
vectors	NULL
and	NULL
selected	NULL
as	NULL
bulk	NULL
cultures	NULL
for	NULL
resistance	NULL
to	NULL
G418	NULL
.	NULL

Southern	NULL
blot	NULL
analysis	NULL
of	NULL
vector	NULL
integration	NULL
showed	NULL
that	NULL
modifications	NULL
in	NULL
the	NULL
3	NULL
'	NULL
LTRs	NULL
were	NULL
correctly	NULL
transferred	NULL
to	NULL
the	NULL
5	NULL
'	NULL
LTRs	NULL
,	NULL
originating	NULL
intact	NULL
proviruses	NULL
integrated	NULL
at	NULL
multiple	NULL
sites	NULL
in	NULL
all	NULL
target	NULL
cell	NULL
populations	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
vector-specific	NULL
transcripts	NULL
was	NULL
analyzed	NULL
by	NULL
Northern	NULL
blotting	NULL
of	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
and	NULL
hybridization	NULL
to	NULL
a	NULL
NeoR-specific	NULL
probe	NULL
.	NULL

LTR-driven	NULL
transcripts	NULL
were	NULL
never	NULL
detected	NULL
in	NULL
cells	NULL
transduced	NULL
with	NULL
the	NULL
ASFCM	NULL
vector	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
lanes	NULL
A	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
deletion	NULL
of	NULL
viral	NULL
enhancer/CAAT	NULL
sequence	NULL
virtually	NULL
abrogated	NULL
transcription	NULL
from	NULL
the	NULL
LTR	NULL
promoter	NULL
.	NULL

Genomic	NULL
transcripts	NULL
derived	NULL
from	NULL
the	NULL
modified	NULL
LTR	NULL
of	NULL
the	NULL
GATA-SFECM	NULL
vector	NULL
were	NULL
detected	NULL
only	NULL
in	NULL
K562	NULL
cells	NULL
,	NULL
and	NULL
not	NULL
in	NULL
Kasumi-1	NULL
,	NULL
MOLT-3	NULL
,	NULL
NIH	NULL
3T3	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
lanes	NULL
G	NULL
)	NULL
,	NULL
and	NULL
U937	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
cells	NULL
.	NULL

K562	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
and	NULL
MEL	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
were	NULL
the	NULL
only	NULL
cell	NULL
lines	NULL
to	NULL
express	NULL
GATA-1	NULL
transcripts	NULL
at	NULL
detectable	NULL
levels	NULL
.	NULL

Subgenomic	NULL
,	NULL
SV40	NULL
promoter-driven	NULL
transcripts	NULL
were	NULL
present	NULL
in	NULL
all	NULL
samples	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

Transcripts	NULL
from	NULL
the	NULL
GATA-modified	NULL
LTR	NULL
were	NULL
accumulated	NULL
in	NULL
K562	NULL
cells	NULL
at	NULL
levels	NULL
of	NULL
approximately	NULL
50	NULL
%	NULL
of	NULL
those	NULL
derived	NULL
from	NULL
the	NULL
wild-type	NULL
LTR	NULL
,	NULL
as	NULL
quantitated	NULL
by	NULL
phosphorimaging	NULL
after	NULL
normalization	NULL
for	NULL
GAPDH	NULL
mRNA	NULL
contents	NULL
(	NULL
Fig	NULL
1A	NULL
,	NULL
lanes	NULL
G	NULL
v	NULL
S	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
lines	NULL
.	NULL

40	NULL
7	NULL
Count	NULL
50	NULL
K562	NULL
3T3	NULL
3279	NULL
significant	NULL
difference	NULL
in	NULL
size	NULL
between	NULL
the	NULL
LTR-driven	NULL
transcripts	NULL
of	NULL
GATA-SFCM	NULL
and	NULL
SFCM	NULL
vectors	NULL
is	NULL
due	NULL
to	NULL
the	NULL
use	NULL
of	NULL
a	NULL
full-length	NULL
(	NULL
1.5	NULL
kb	NULL
)	NULL
rather	NULL
than	NULL
a	NULL
truncated	NULL
(	NULL
0.9	NULL
kb	NULL
)	NULL
version	NULL
of	NULL
the	NULL
LNGFR	NULL
cDNA	NULL
in	NULL
the	NULL
SECM	NULL
vector	NULL
used	NULL
in	NULL
this	NULL
particular	NULL
experiment	NULL
.	NULL

Cell	NULL
surface	NULL
expression	NULL
of	NULL
ALNGFR	NULL
was	NULL
quantitatively	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
in	NULL
all	NULL
G418-selected	NULL
cell	NULL
lines	NULL
.	NULL

Expression	NULL
from	NULL
the	NULL
GATA-SFCM	NULL
vector	NULL
was	NULL
observed	NULL
only	NULL
in	NULL
K562	NULL
and	NULL
MEL	NULL
cells	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
dotted	NULL
lines	NULL
)	NULL
,	NULL
with	NULL
mean	NULL
fluorescence	NULL
values	NULL
approximately	NULL
sixfold	NULL
and	NULL
threefold	NULL
lower	NULL
,	NULL
respectively	NULL
(	NULL
169	NULL
v	NULL
1,001	NULL
and	NULL
50	NULL
v	NULL
135	NULL
arbitrary	NULL
units	NULL
[	NULL
AU	NULL
]	NULL
)	NULL
,	NULL
than	NULL
those	NULL
of	NULL
SFECM-transduced	NULL
cells	NULL
(	NULL
Fig	NULL
2	NULL
,	NULL
bold	NULL
lines	NULL
)	NULL
.	NULL

In	NULL
all	NULL
the	NULL
other	NULL
cases	NULL
,	NULL
ALNGFR	NULL
expression	NULL
profiles	NULL
of	NULL
GATA-SFCM-transduced	NULL
and	NULL
ASFCM-transduced	NULL
cells	NULL
were	NULL
indistinguishable	NULL
(	NULL
NIH3T3	NULL
and	NULL
Kasumi-1	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
2	NULL
as	NULL
an	NULL
example	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
GATA-SFCM	NULL
vector	NULL
is	NULL
restricted	NULL
to	NULL
the	NULL
erythroblastic	NULL
progeny	NULL
of	NULL
transduced	NULL
human	NULL
CD34*	NULL
cells	NULL
.	NULL

Human	NULL
CD34*	NULL
cells	NULL
from	NULL
cord	NULL
blood	NULL
were	NULL
transduced	NULL
by	NULL
multiple	NULL
cycles	NULL
of	NULL
infection	NULL
with	NULL
viral	NULL
supernatants	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cytokines	NULL
(	NULL
huIL-3	NULL
,	NULL
hulL-6	NULL
,	NULL
and	NULL
huSCF	NULL
)	NULL
and	NULL
in	NULL
coculture	NULL
with	NULL
the	NULL
murine	NULL
stromal	NULL
cell	NULL
clone	NULL
CBR-BM	NULL
,	NULL
D	NULL
#	NULL
1	NULL
.	NULL

This	NULL
clone	NULL
was	NULL
previously	NULL
described	NULL
to	NULL
support	NULL
survival	NULL
and	NULL
proliferation	NULL
of	NULL
human	NULL
CD34*/CD38	NULL
!	NULL
``	NULL

''	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
,	NULL
``	NULL
leading	NULL
to	NULL
higher	NULL
yield	NULL
and	NULL
increased	NULL
gene	NULL
transfer	NULL
efficiency	NULL
compared	NULL
with	NULL
standard	NULL
protocols	NULL
based	NULL
on	NULL
cytokines	NULL
only	NULL
(	NULL
Aiuti	NULL
et	NULL
al	NULL
,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

SFCM-transduced	NULL
and	NULL
GATA-SFCM-transduced	NULL
CD34*	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
expression	NULL
of	NULL
ALNGFR	NULL
by	NULL
multiparameter	NULL
flow	NULL
cytometry	NULL
48	NULL
hours	NULL
after	NULL
infection	NULL
.	NULL

The	NULL
efficiency	NULL
of	NULL
transduction	NULL
of	NULL
primitive	NULL
MEL	NULL
Kasumi-1	NULL
1000	NULL
_	NULL
.1	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
NGFR-FiTC	NULL
Fig	NULL
2	NULL
.	NULL

FACS	NULL
analysis	NULL
of	NULL
surface	NULL
ALNGFR	NULL
expression	NULL
in	NULL
erythroblastic	NULL
(	NULL
K562	NULL
and	NULL
MEL	NULL
)	NULL
and	NULL
nonerythroblastic	NULL
(	NULL
3T3	NULL
and	NULL
Kasumi-1	NULL
)	NULL
cell	NULL
lines	NULL
transduced	NULL
by	NULL
ASFCM	NULL
(	NULL
solid	NULL
lines	NULL
)	NULL
,	NULL
GATA-SFCM	NULL
(	NULL
dotted	NULL
lines	NULL
)	NULL
,	NULL
and	NULL
SFCM	NULL
(	NULL
bold	NULL
lines	NULL
)	NULL
vectors	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
FITC-conjugated	NULL
anti-LNGFR	NULL
antibody	NULL
.	NULL

3280	NULL
GRANDE	NULL
ET	NULL
AL	NULL
1000	NULL
SSC	NULL
CD38-TC	NULL
104	NULL
a	NULL
a	NULL
q	NULL
g	NULL
3	NULL
.	NULL

Multiparametric	NULL
FACS	NULL
analysis	NULL
of	NULL
human	NULL
cord	NULL
blood	NULL
CD34*	NULL
cells	NULL
48	NULL
hours	NULL
after	NULL
transduction	NULL
with	NULL
SFCM	NULL
and	NULL
GATA-SFCM	NULL
vectors	NULL
.	NULL

The	NULL
forward	NULL
(	NULL
FSC	NULL
)	NULL
and	NULL
side	NULL
(	NULL
SSC	NULL
)	NULL
scatter	NULL
plot	NULL
is	NULL
in	NULL
GATA-SFCM	NULL
0	NULL
%	NULL
55.5	NULL
%	NULL
CD34-PE	NULL
the	NULL
upper-left	NULL
panel	NULL
.	NULL

Expression	NULL
of	NULL
ALNGFR	NULL
(	NULL
lower	NULL
panels	NULL
)	NULL
was	NULL
analyzed	NULL
in	NULL
the	NULL
low-SSC	NULL
,	NULL
CD34+	NULL
,	NULL
CD38	NULL
``	NULL
gated	NULL
cell	NULL
population	NULL
(	NULL
boxed	NULL
in	NULL
the	NULL
upper-right	NULL
panel	NULL
)	NULL
.	NULL

1	NULL
The	NULL
percentage	NULL
of	NULL
ALNGFR*	NULL
cells	NULL
-	NULL
(	NULL
boxed	NULL
)	NULL
is	NULL
indicated	NULL
in	NULL
the	NULL
lower	NULL
3	NULL
panels	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
FITC-conjugated	NULL
anti-LNGFR	NULL
,	NULL
TC	NULL
23.8	NULL
%	NULL
10Â°	NULL
100	NULL
104	NULL
10Â°	NULL
104	NULL
100	NULL
â	NULL
104	NULL
conjugated	NULL
anti-CD38	NULL
(	NULL
X	NULL
axis	NULL
)	NULL
and	NULL
PE-conjugated	NULL
anti-CD34	NULL
(	NULL
Y	NULL
NGFR-FITC	NULL
hematopoietic	NULL
progenitors	NULL
,	NULL
identified	NULL
by	NULL
a	NULL
low	NULL
side	NULL
scatter	NULL
profile	NULL
and	NULL
the	NULL
CD34+*/CD38	NULL
``	NULL
*	NULL
``	NULL
phenotype	NULL
(	NULL
Fig	NULL
3	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
,	NULL
ranged	NULL
from	NULL
55	NULL
%	NULL
(	NULL
SFECM-transduced	NULL
cells	NULL
)	NULL
to	NULL
23	NULL
%	NULL
(	NULL
GATA-SFCM-transduced	NULL
cells	NULL
;	NULL
Fig	NULL
3	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
,	NULL
correlating	NULL
with	NULL
the	NULL
difference	NULL
in	NULL
viral	NULL
titer	NULL
.	NULL

Both	NULL
wild-type	NULL
and	NULL
the	NULL
enhancer-replaced	NULL
LTRs	NULL
were	NULL
expressed	NULL
in	NULL
CD34*/CD38	NULL
!	NULL

*	NULL
``	NULL
cells	NULL
,	NULL
although	NULL
at	NULL
different	NULL
levels	NULL
(	NULL
mean	NULL
fluorescence	NULL
of	NULL
1,003	NULL
and	NULL
214	NULL
AU	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
efficient	NULL
transduction	NULL
of	NULL
primitive	NULL
hematopoietic	NULL
progenitors	NULL
,	NULL
which	NULL
were	NULL
induced	NULL
to	NULL
proliferate	NULL
without	NULL
losing	NULL
the	NULL
primitive	NULL
,	NULL
CD34	NULL
+/CD38	NULL
'	NULL
``	NULL
``	NULL
pheno-type	NULL
.	NULL

To	NULL
test	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
chimeric	NULL
LTR	NULL
in	NULL
the	NULL
differentiated	NULL
progeny	NULL
of	NULL
human	NULL
hematopoietic	NULL
progenitors	NULL
,	NULL
transduced	NULL
CD34*	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
liquid	NULL
culture	NULL
in	NULL
conditions	NULL
that	NULL
allow	NULL
both	NULL
myeloid	NULL
and	NULL
erythroid	NULL
differentiation	NULL
.	NULL

ALNGFR	NULL
expression	NULL
was	NULL
evaluated	NULL
by	NULL
FACS	NULL
analysis	NULL
of	NULL
cells	NULL
double-stained	NULL
with	NULL
antibodies	NULL
against	NULL
either	NULL
erythroid	NULL
(	NULL
GpAÂ¥	NULL
)	NULL
or	NULL
myeloid	NULL
(	NULL
CD13	NULL
)	NULL
lineage-specific	NULL
surface	NULL
markers	NULL
.	NULL

A	NULL
representative	NULL
experiment	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
4	NULL
.	NULL

After	NULL
6	NULL
days	NULL
of	NULL
culture	NULL
and	NULL
48	NULL
hours	NULL
after	NULL
transduction	NULL
(	NULL
day	NULL
6	NULL
,	NULL
left	NULL
panel	NULL
in	NULL
Fig	NULL
4	NULL
)	NULL
,	NULL
the	NULL
proportion	NULL
of	NULL
CD34*	NULL
cells	NULL
expressing	NULL
the	NULL
ALNGFR	NULL
marker	NULL
ranged	NULL
from	NULL
32	NULL
%	NULL
in	NULL
cultures	NULL
infected	NULL
with	NULL
SFCM	NULL
to	NULL
13	NULL
%	NULL
in	NULL
cultures	NULL
infected	NULL
with	NULL
GATA-SFCM	NULL
,	NULL
with	NULL
mean	NULL
fluorescence	NULL
values	NULL
of	NULL
1,613	NULL
and	NULL
555	NULL
AU	NULL
,	NULL
respectively	NULL
.	NULL

After	NULL
induction	NULL
of	NULL
differentiation	NULL
,	NULL
ALNGFR	NULL
was	NULL
expressed	NULL
in	NULL
a	NULL
comparable	NULL
fraction	NULL
of	NULL
GpA*	NULL
and	NULL
CD13*	NULL
cells	NULL
derived	NULL
from	NULL
SFCM-transduced	NULL
progenitors	NULL
(	NULL
35.4	NULL
%	NULL
v	NULL
30	NULL
%	NULL
)	NULL
,	NULL
whereas	NULL
it	NULL
was	NULL
expressed	NULL
preferentially	NULL
in	NULL
GpA*	NULL
and	NULL
only	NULL
in	NULL
a	NULL
few	NULL
CD13*	NULL
cells	NULL
(	NULL
14.7	NULL
%	NULL
v	NULL
3.6	NULL
%	NULL
)	NULL
derived	NULL
from	NULL
GATA-SFCM-transduced	NULL
progenitors	NULL
(	NULL
day	NULL
8	NULL
,	NULL
middle	NULL
and	NULL
right	NULL
panels	NULL
in	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

Quantitative	NULL
expression	NULL
of	NULL
ALNGFR	NULL
was	NULL
comparable	NULL
in	NULL
GpA*	NULL
cells	NULL
transduced	NULL
with	NULL
SECM	NULL
and	NULL
GATA-SFCM	NULL
(	NULL
246	NULL
v	NULL
218	NULL
AU	NULL
)	NULL
,	NULL
whereas	NULL
in	NULL
CD13*	NULL
>	NULL
axis	NULL
)	NULL
antibodies	NULL
.	NULL

C	NULL
,	NULL
control	NULL
,	NULL
un-transduced	NULL
cells	NULL
.	NULL

cells	NULL
transduced	NULL
with	NULL
GATA-SFCM	NULL
,	NULL
it	NULL
was	NULL
fivefold	NULL
lower	NULL
than	NULL
in	NULL
those	NULL
transduced	NULL
with	NULL
SFCM	NULL
(	NULL
155	NULL
v	NULL
730	NULL
AU	NULL
)	NULL
.	NULL

To	NULL
provide	NULL
an	NULL
independent	NULL
assay	NULL
of	NULL
the	NULL
expression	NULL
properties	NULL
of	NULL
the	NULL
enhancer-replaced	NULL
LTR	NULL
,	NULL
transduced	NULL
CD34*	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
clonal	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G418	NULL
.	NULL

Colonies	NULL
were	NULL
morphologically	NULL
scored	NULL
as	NULL
BFU-E	NULL
,	NULL
CFU-GM	NULL
,	NULL
or	NULL
CFU-GEMM	NULL
between	NULL
10	NULL
and	NULL
14	NULL
days	NULL
from	NULL
plating	NULL
.	NULL

Transduction	NULL
efficiency	NULL
in	NULL
clonogenic	NULL
progenitors	NULL
(	NULL
percentage	NULL
of	NULL
G418-resistant	NULL
colonies	NULL
)	NULL
ranged	NULL
from	NULL
19	NULL
%	NULL
to	NULL
26	NULL
%	NULL
for	NULL
the	NULL
SFCM	NULL
vector	NULL
and	NULL
from	NULL
7.5	NULL
%	NULL
to	NULL
12	NULL
%	NULL
for	NULL
the	NULL
GATA-SFCM	NULL
vector	NULL
and	NULL
was	NULL
overall	NULL
higher	NULL
for	NULL
CFU-GM	NULL
(	NULL
15	NULL
%	NULL
to	NULL
51	NULL
%	NULL
)	NULL
than	NULL
for	NULL
BFU-E	NULL
(	NULL
3.5	NULL
%	NULL
to	NULL
12.5	NULL
%	NULL
)	NULL
progenitors	NULL
,	NULL
with	NULL
no	NULL
significant	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
vectors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

BFU-E	NULL
and	NULL
CFU-GM	NULL
colonies	NULL
were	NULL
individually	NULL
picked	NULL
,	NULL
pooled	NULL
(	NULL
60	NULL
to	NULL
80	NULL
colonies/pool	NULL
)	NULL
,	NULL
and	NULL
analyzed	NULL
for	NULL
ALNGFR	NULL
expression	NULL
by	NULL
immunocytochemistry	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
5	NULL
,	NULL
both	NULL
BFU-E	NULL
and	NULL
CFU-GM	NULL
colonies	NULL
derived	NULL
from	NULL
SFCM-transduced	NULL
clonogenic	NULL
progenitors	NULL
expressed	NULL
cyto-plasmic	NULL
and	NULL
surface	NULL
ALNGFR	NULL
(	NULL
upper	NULL
panels	NULL
)	NULL
.	NULL

Conversely	NULL
,	NULL
only	NULL
BFU-E	NULL
colonies	NULL
derived	NULL
from	NULL
GATA-SFCM-transduced	NULL
progenitors	NULL
were	NULL
positive	NULL
for	NULL
ALNGFR	NULL
staining	NULL
(	NULL
Fig	NULL
5	NULL
,	NULL
lower	NULL
panels	NULL
)	NULL
.	NULL

Colony	NULL
identification	NULL
was	NULL
confirmed	NULL
by	NULL
staining	NULL
for	NULL
GpA	NULL
and	NULL
CD13	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
study	NULL
gene	NULL
expression	NULL
at	NULL
the	NULL
level	NULL
of	NULL
single	NULL
colonies	NULL
,	NULL
CD34*	NULL
cells	NULL
were	NULL
transduced	NULL
with	NULL
the	NULL
LGSN	NULL
and	NULL
GATA-LGSN	NULL
vectors	NULL
carrying	NULL
the	NULL
EGFP	NULL
marker	NULL
gene	NULL
.	NULL

Clonogenic	NULL
assay	NULL
was	NULL
performed	NULL
under	NULL
the	NULL
same	NULL
conditions	NULL
described	NULL
for	NULL
ALNGFR	NULL
vectors	NULL
,	NULL
and	NULL
G418-resistant	NULL
,	NULL
EGFP*	NULL
colonies	NULL
were	NULL
scored	NULL
in	NULL
situ	NULL
under	NULL
an	NULL
inverted	NULL
fluorescence	NULL
microscope	NULL
.	NULL

In	NULL
a	NULL
representative	NULL
experiment	NULL
,	NULL
EGFP	NULL
was	NULL
expressed	NULL
in	NULL
both	NULL
CFU-GM	NULL
(	NULL
99	NULL
of	NULL
102	NULL
)	NULL
and	NULL
BFU-E	NULL
(	NULL
48	NULL
of	NULL
50	NULL
)	NULL
colonies	NULL
differentiated	NULL
from	NULL
LGSN-transduced	NULL
progenitors	NULL
and	NULL
in	NULL
most	NULL
of	NULL
the	NULL
accessory	NULL
cells	NULL
in	NULL
the	NULL
plates	NULL
(	NULL
Fig	NULL
6A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
EGFP	NULL
TRANSCRIPTIONAL	NULL
TARGETING	NULL
OF	NULL
RETROVIRAL	NULL
VECTORS	NULL
DAY	NULL
6	NULL
10	NULL
%	NULL
0.8	NULL
%	NULL
Fig	NULL
4	NULL
.	NULL

Expression	NULL
of	NULL
ALNGFR	NULL
in	NULL
liquid	NULL
cultures	NULL
of	NULL
control	NULL
(	NULL
C	NULL
)	NULL
,	NULL
SFCM-transduced	NULL
,	NULL
and	NULL
GATA-SFCM-transduced	NULL
CD34+	NULL
cells	NULL
.	NULL

Cultures	NULL
were	NULL
analyzed	NULL
48	NULL
hours	NULL
after	NULL
transduction	NULL
for	NULL
expression	NULL
of	NULL
ALNGFR	NULL
and	NULL
CD34	NULL
(	NULL
day	NULL
6	NULL
)	NULL
and	NULL
2	NULL
days	NULL
after	NULL
induction	NULL
of	NULL
differentiation	NULL
for	NULL
expression	NULL
of	NULL
ALNGFR	NULL
and	NULL
the	NULL
lineage-specific	NULL
markers	NULL
GpA	NULL
and	NULL
CD13	NULL
(	NULL
day	NULL
8	NULL
)	NULL
.	NULL

CD34+	NULL
,	NULL
GpA*	NULL
,	NULL
and	NULL
CD13+	NULL
cells	NULL
are	NULL
show	NULL
n	NULL
in	NULL
blue	NULL
,	NULL
red	NULL
,	NULL
and	NULL
green	NULL
colors	NULL
,	NULL
respectively	NULL
.	NULL

Values	NULL
indicate	NULL
the	NULL
percentage	NULL
of	NULL
ALNGFR*	NULL
cells	NULL
in	NULL
the	NULL
CD34+	NULL
,	NULL
GpA*	NULL
,	NULL
or	NULL
CD13+	NULL
fractions	NULL
(	NULL
boxed	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
_	NULL
FITC-conjugated	NULL
-	NULL
anti-LNGFR	NULL
(	NULL
X	NULL
axis	NULL
)	NULL
and	NULL
PE-conju-	NULL
CD34-PE	NULL
GpA-PE	NULL
3281	NULL
0.2	NULL
%	NULL
0+	NULL
CD13-PE	NULL
GATA-	NULL
10+	NULL
gated	NULL
anti-CD34	NULL
,	NULL
GpA	NULL
,	NULL
and	NULL
CD13	NULL
(	NULL
Y	NULL
axis	NULL
)	NULL
antibodies	NULL
.	NULL

expression	NULL
was	NULL
detected	NULL
only	NULL
in	NULL
BFU-E	NULL
colonies	NULL
(	NULL
13	NULL
of	NULL
14	NULL
v	NULL
1	NULL
of	NULL
30	NULL
CFU-GM	NULL
colonies	NULL
)	NULL
in	NULL
the	NULL
progeny	NULL
of	NULL
GATA-LGSN-transduced	NULL
CD34	NULL
*	NULL
cells	NULL
(	NULL
Fig	NULL
6C	NULL
through	NULL
F	NULL
)	NULL
.	NULL

Overall	NULL
,	NULL
these	NULL
results	NULL
show	NULL
that	NULL
the	NULL
GATA-SFCM	NULL
LTR	NULL
is	NULL
expressed	NULL
in	NULL
CD34*	NULL
hematopoietic	NULL
progenitors	NULL
,	NULL
strongly	NULL
down	NULL
BFU-E	NULL
CFU-GM	NULL
SFCM	NULL
GATA-SFCM	NULL
Fig	NULL
5	NULL
.	NULL

Immunocytochemical	NULL
staining	NULL
for	NULL
ALNGFR	NULL
in	NULL
pools	NULL
of	NULL
BFU-E	NULL
(	NULL
left	NULL
)	NULL
and	NULL
CFU-GM	NULL
(	NULL
right	NULL
)	NULL
colonies	NULL
from	NULL
methylcellulose	NULL
clonal	NULL
cultures	NULL
of	NULL
CD34+	NULL
hematopoietic	NULL
progenitors	NULL
transduced	NULL
with	NULL
the	NULL
SFCM	NULL
(	NULL
upper	NULL
panels	NULL
)	NULL
and	NULL
GATA-SFCM	NULL
(	NULL
lower	NULL
panels	NULL
)	NULL
vectors	NULL
.	NULL

ALNGFR*	NULL
cells	NULL
appear	NULL
in	NULL
red	NULL
after	NULL
APAAP	NULL
staining	NULL
.	NULL

The	NULL
bar	NULL
is	NULL
10	NULL
pm	NULL
.	NULL

NGFR-FITC	NULL
regulated	NULL
in	NULL
cells	NULL
undergoing	NULL
myelo-monocytic	NULL
differentiation	NULL
,	NULL
and	NULL
persistently	NULL
expressed	NULL
,	NULL
at	NULL
levels	NULL
comparable	NULL
to	NULL
those	NULL
of	NULL
a	NULL
wild-type	NULL
LTR	NULL
,	NULL
in	NULL
cells	NULL
undergoing	NULL
erythroid	NULL
differentiation	NULL
.	NULL

Lineage	NULL
restriction	NULL
of	NULL
ALNGFR	NULL
expression	NULL
in	NULL
mice	NULL
engrafted	NULL
with	NULL
GATA-SFCM-transduced	NULL
BM	NULL
cells	NULL
.	NULL

To	NULL
test	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
enhancer-replaced	NULL
LTR	NULL
in	NULL
the	NULL
progeny	NULL
of	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
in	NULL
vivo	NULL
,	NULL
1	NULL
to	NULL
1.5	NULL
X	NULL
10	NULL
``	NULL
BM	NULL
cells	NULL
from	NULL
C57BV6-Ly-5.1	NULL
(	NULL
CD45.1*	NULL
)	NULL
donor	NULL
mice	NULL
were	NULL
transduced	NULL
by	NULL
coculture	NULL
with	NULL
ecotropic	NULL
SFCM	NULL
and	NULL
GATA-SFCM	NULL
packaging	NULL
cells	NULL
and	NULL
transplanted	NULL
into	NULL
lethally	NULL
irradiated	NULL
â¬57B1/6	NULL
(	NULL
CD45.2+	NULL
)	NULL
GATA-LGSN	NULL
GATALGSN	NULL
Fig	NULL
6	NULL
.	NULL

Expression	NULL
of	NULL
EGFP	NULL
in	NULL
G418-resistant	NULL
colonies	NULL
grown	NULL
in	NULL
methylcellulose	NULL
from	NULL
CD34+	NULL
hematopoietic	NULL
progenitors	NULL
transduced	NULL
with	NULL
LGSN	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
GATA-LGSN	NULL
(	NULL
C	NULL
through	NULL
F	NULL
)	NULL
vectors	NULL
.	NULL

Green-fluorescence	NULL
and	NULL
bright-field	NULL
views	NULL
of	NULL
the	NULL
same	NULL
fields	NULL
are	NULL
shown	NULL
in	NULL
the	NULL
left	NULL
and	NULL
right	NULL
panels	NULL
,	NULL
respectively	NULL
.	NULL

3282	NULL
recipient	NULL
mice	NULL
.	NULL

Transduction	NULL
efficiency	NULL
of	NULL
murine	NULL
progenitors	NULL
,	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
G418-resistant	NULL
colonies	NULL
in	NULL
methylcellulose	NULL
assay	NULL
,	NULL
averaged	NULL
80	NULL
%	NULL
for	NULL
SECM	NULL
and	NULL
23	NULL
%	NULL
for	NULL
GATA-SECM	NULL
vectors	NULL
,	NULL
respectively	NULL
.	NULL

Eight	NULL
weeks	NULL
posttransplant	NULL
,	NULL
BM	NULL
cells	NULL
from	NULL
recipient	NULL
animals	NULL
were	NULL
analyzed	NULL
for	NULL
expression	NULL
of	NULL
ALNGFR	NULL
and	NULL
erythroid	NULL
(	NULL
TER-119	NULL
)	NULL
and	NULL
myeloid	NULL
(	NULL
Gr-1	NULL
)	NULL
lineage-specific	NULL
markers	NULL
.	NULL

Engraftment	NULL
of	NULL
donor	NULL
cells	NULL
in	NULL
the	NULL
BM	NULL
,	NULL
indicated	NULL
by	NULL
the	NULL
proportion	NULL
of	NULL
CD45.1*/total	NULL
CD45*	NULL
cells	NULL
,	NULL
averaged	NULL
66.5	NULL
%	NULL
+	NULL
9.1	NULL
%	NULL
,	NULL
with	NULL
no	NULL
significant	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
groups	NULL
of	NULL
mice	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
mice	NULL
transplanted	NULL
with	NULL
SFCM-transduced	NULL
BM	NULL
,	NULL
the	NULL
proportion	NULL
of	NULL
ALNGFR	NULL
*	NULL
cells	NULL
averaged	NULL
3	NULL
%	NULL
in	NULL
the	NULL
Sca-1*	NULL
stem	NULL
cells	NULL
,	NULL
6	NULL
%	NULL
in	NULL
the	NULL
TER-119+*	NULL
cells	NULL
,	NULL
and	NULL
4	NULL
%	NULL
in	NULL
the	NULL
Gr-1*	NULL
cells	NULL
(	NULL
Fig	NULL
7	NULL
,	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

In	NULL
recipients	NULL
of	NULL
GATA-SFCM-transduced	NULL
BM	NULL
,	NULL
ALNGFR*	NULL
cells	NULL
were	NULL
detected	NULL
at	NULL
significant	NULL
level	NULL
(	NULL
7	NULL
%	NULL
)	NULL
only	NULL
in	NULL
the	NULL
erythroblas-tic	NULL
,	NULL
TER119+*	NULL
cell	NULL
population	NULL
(	NULL
Fig	NULL
7	NULL
,	NULL
left	NULL
panels	NULL
)	NULL
.	NULL

Quantitative	NULL
expression	NULL
of	NULL
ALNGFR	NULL
was	NULL
comparable	NULL
in	NULL
TER119*	NULL
cells	NULL
transduced	NULL
with	NULL
SFCM	NULL
and	NULL
GATA-SFCM	NULL
(	NULL
69	NULL
v	NULL
116	NULL
AU	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
GATA-1-modified	NULL
LTR	NULL
is	NULL
restricted	NULL
to	NULL
the	NULL
erythroblastic	NULL
lineage	NULL
also	NULL
in	NULL
the	NULL
progeny	NULL
of	NULL
transduced	NULL
mouse-repopulating	NULL
stem	NULL
cells	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
GATA-1-modified	NULL
LTR	NULL
at	NULL
all	NULL
GataA-sFem	NULL
sFCM	NULL
*	NULL
0.7	NULL
%	NULL
2.6	NULL
%	NULL
LW	NULL
E	NULL
a	NULL
j	NULL
]	NULL
el	NULL
]	NULL
1	NULL
o	NULL
``	NULL
4	NULL
3	NULL
w	NULL
4	NULL
ml	NULL
1	NULL
o	NULL
H	NULL
Fo	NULL
3	NULL
C|	NULL
0.4	NULL
%	NULL
{	NULL
_	NULL
w	NULL
o	NULL
1	NULL
a	NULL
|	NULL
3	NULL
5	NULL
}	NULL
1	NULL
a	NULL
*	NULL
*	NULL
Â°	NULL
Tt	NULL
aot	NULL
0000000000	NULL
00	NULL
ao	NULL
``	NULL
i	NULL
>	NULL
NGFR-FITC	NULL
Fig	NULL
7	NULL
.	NULL

-	NULL
Expression	NULL
of	NULL
ALNGFR	NULL
in	NULL
the	NULL
BM	NULL
of	NULL
a	NULL
mouse	NULL
2	NULL
months	NULL
after	NULL
transplantation	NULL
of	NULL
SFCM-transduced	NULL
(	NULL
right	NULL
)	NULL
and	NULL
GATA-SFCM-transduced	NULL
(	NULL
left	NULL
)	NULL
BM	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
FITC-conjugated	NULL
anti-ALNGEFR	NULL
(	NULL
X	NULL
axis	NULL
)	NULL
and	NULL
PE-conjugated	NULL
anti-Scai	NULL
,	NULL
TER	NULL
119	NULL
,	NULL
and	NULL
Gr-1	NULL
(	NULL
Y	NULL
axis	NULL
)	NULL
antibodies	NULL
.	NULL

Positivity	NULL
to	NULL
Scat	NULL
and	NULL
TER	NULL
119	NULL
was	NULL
analyzed	NULL
in	NULL
the	NULL
blast/lymphocyte-gated	NULL
cells	NULL
,	NULL
and	NULL
positivity	NULL
to	NULL
GR-1	NULL
was	NULL
analyzed	NULL
in	NULL
the	NULL
granulocyte-gated	NULL
cells	NULL
.	NULL

GRANDE	NULL
ET	NULL
AL	NULL
ai	NULL
TER119-PE	NULL
00	NULL
0	NULL
1	NULL
0	NULL
ssc	NULL
1000	NULL
0Â°	NULL
norr-ritc	NULL
104	NULL
104	NULL
apolar	NULL
TER119-PE	NULL
at	NULL
3	NULL
3	NULL
4	NULL
4	NULL
0	NULL
100	NULL
0	NULL
ssc	NULL
1000	NULL
100	NULL
Nerr-Fite	NULL
10+	NULL
C	NULL
7.8	NULL
%	NULL
TER119-PE	NULL
(	NULL
rrrl	NULL
-	NULL
&	NULL
1	NULL
.	NULL

%	NULL
1000	NULL
10Â°	NULL
nerr-rirc	NULL
10+	NULL
Fig	NULL
8	NULL
.	NULL

Expression	NULL
of	NULL
ALNGFR	NULL
in	NULL
erythoid	NULL
cells	NULL
(	NULL
TER119*	NULL
)	NULL
at	NULL
different	NULL
stages	NULL
of	NULL
differentiation	NULL
,	NULL
obtained	NULL
from	NULL
the	NULL
BM	NULL
of	NULL
a	NULL
mouse	NULL
2	NULL
months	NULL
after	NULL
transplantation	NULL
of	NULL
GATA-SFCM-transduced	NULL
BM	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
FITC-conjugated	NULL
anti-ALNGFR	NULL
(	NULL
X	NULL
axis	NULL
on	NULL
the	NULL
right	NULL
panels	NULL
)	NULL
and	NULL
PE-conjugated	NULL
anti-TER	NULL
119	NULL
(	NULL
Y	NULL
axis	NULL
on	NULL
the	NULL
right	NULL
panels	NULL
)	NULL
antibodies	NULL
.	NULL

Positivity	NULL
to	NULL
both	NULL
markers	NULL
was	NULL
analyzed	NULL
in	NULL
three	NULL
separate	NULL
BM	NULL
fractions	NULL
,	NULL
gated	NULL
according	NULL
to	NULL
their	NULL
forward	NULL
scatter	NULL
(	NULL
SSC	NULL
,	NULL
Y	NULL
axis	NULL
in	NULL
the	NULL
left	NULL
panels	NULL
)	NULL
profile	NULL
and	NULL
containing	NULL
,	NULL
respectively	NULL
,	NULL
large	NULL
erythroblasts	NULL
(	NULL
A	NULL
)	NULL
,	NULL
mature	NULL
erythroblasts	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
erythrocytes	NULL
(	NULL
C	NULL
)	NULL
.	NULL

stages	NULL
of	NULL
erythroblast	NULL
differentiation	NULL
,	NULL
expression	NULL
of	NULL
TER119	NULL
and	NULL
ALNGFR	NULL
was	NULL
assayed	NULL
in	NULL
three	NULL
different	NULL
subpopulations	NULL
of	NULL
BM	NULL
cells	NULL
,	NULL
gated	NULL
according	NULL
to	NULL
their	NULL
forward-scatter	NULL
(	NULL
FSC	NULL
)	NULL
profile	NULL
.	NULL

These	NULL
populations	NULL
contain	NULL
erythroid	NULL
cells	NULL
at	NULL
different	NULL
,	NULL
morphologically	NULL
recognizable	NULL
stages	NULL
of	NULL
maturation	NULL
.	NULL
``	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
8	NULL
,	NULL
immature	NULL
large	NULL
erythroblasts	NULL
(	NULL
fraction	NULL
A	NULL
)	NULL
,	NULL
more	NULL
mature	NULL
small	NULL
erythroblasts	NULL
(	NULL
fraction	NULL
B	NULL
)	NULL
,	NULL
and	NULL
mature	NULL
erythrocytes	NULL
(	NULL
fraction	NULL
C	NULL
)	NULL
contain	NULL
a	NULL
comparable	NULL
percentage	NULL
of	NULL
cells	NULL
expressing	NULL
ALNGFR	NULL
(	NULL
between	NULL
7	NULL
%	NULL
and	NULL
8	NULL
%	NULL
)	NULL
.	NULL

However	NULL
,	NULL
quantitative	NULL
levels	NULL
of	NULL
ALNGFR	NULL
appeared	NULL
to	NULL
decrease	NULL
with	NULL
the	NULL
maturation	NULL
stage	NULL
(	NULL
mean	NULL
fluorescence	NULL
decreasing	NULL
from	NULL
86	NULL
AU	NULL
in	NULL
fraction	NULL
A	NULL
to	NULL
22	NULL
AU	NULL
in	NULL
fraction	NULL
C	NULL
;	NULL
see	NULL
Fig	NULL
8	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
GATA-1-responsive	NULL
LTR	NULL
is	NULL
active	NULL
at	NULL
all	NULL
stages	NULL
of	NULL
murine	NULL
erythroid	NULL
differentiation	NULL
.	NULL

DISCUSSION	NULL
Transcriptional	NULL
control	NULL
of	NULL
an	NULL
integrated	NULL
retroviral	NULL
vector	NULL
is	NULL
mastered	NULL
by	NULL
the	NULL
5	NULL
LTR	NULL
of	NULL
the	NULL
provirus	NULL
,	NULL
which	NULL
exerts	NULL
a	NULL
strong	NULL
influence	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
any	NULL
additional	NULL
enhancer/promoter	NULL
element	NULL
placed	NULL
within	NULL
the	NULL
viral	NULL
transcription	NULL
unit	NULL
.	NULL

Traditional	NULL
ways	NULL
to	NULL
overcome	NULL
this	NULL
transcriptional	NULL
interference	NULL
include	NULL
disabling	NULL
the	NULL
LTR	NULL
by	NULL
enhancer	NULL
deletion	NULL
or	NULL
cloning	NULL
alternative	NULL
transcription	NULL
units	NULL
upstream	NULL
of	NULL
the	NULL
5	NULL
'	NULL
LTR	NULL
U3	NULL
region	NULL
or	NULL
in	NULL
the	NULL
TRANSCRIPTIONAL	NULL
TARGETING	NULL
OF	NULL
RETROVIRAL	NULL
VECTORS	NULL
opposite	NULL
transcriptional	NULL
orientation	NULL
.	NULL

Each	NULL
design	NULL
has	NULL
advantages	NULL
and	NULL
limitations	NULL
,	NULL
and	NULL
none	NULL
can	NULL
be	NULL
considered	NULL
of	NULL
general	NULL
applica-bility.Â©	NULL
We	NULL
have	NULL
tried	NULL
to	NULL
redirect	NULL
,	NULL
rather	NULL
than	NULL
disable	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
5Â°	NULL
LTR	NULL
promoter	NULL
by	NULL
replacing	NULL
the	NULL
constitutive	NULL
U3	NULL
extended	NULL
enhancer	NULL
(	NULL
direct	NULL
repeats	NULL
+	NULL
CAAT	NULL
box	NULL
)	NULL
with	NULL
the	NULL
200-bp	NULL
ARE	NULL
from	NULL
the	NULL
murine	NULL
GATA-1	NULL
gene	NULL
.	NULL

Retroviral	NULL
vectors	NULL
in	NULL
which	NULL
the	NULL
enhancer-replaced	NULL
LTR	NULL
drive	NULL
the	NULL
expression	NULL
of	NULL
appropriate	NULL
reporter	NULL
genes	NULL
(	NULL
ALNGFR	NULL
or	NULL
EGFP	NULL
)	NULL
were	NULL
used	NULL
to	NULL
transduce	NULL
human	NULL
primitive	NULL
hematopoietic	NULL
progenitors	NULL
(	NULL
CD34	NULL
*/	NULL
CD38	NULL
``	NULL
)	NULL
and	NULL
mouse-repopulating	NULL
stem	NULL
cells	NULL
.	NULL

Analysis	NULL
of	NULL
transgene	NULL
expression	NULL
in	NULL
vitro	NULL
as	NULL
well	NULL
as	NULL
in	NULL
vivo	NULL
indicated	NULL
that	NULL
the	NULL
GATA-1	NULL
ARE	NULL
effectively	NULL
restricts	NULL
transcription	NULL
from	NULL
the	NULL
LTR	NULL
promoter	NULL
to	NULL
the	NULL
erythroid	NULL
progeny	NULL
of	NULL
the	NULL
transduced	NULL
stem	NULL
cells	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
modified	NULL
LTR	NULL
was	NULL
in	NULL
fact	NULL
quantitatively	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
LTR	NULL
in	NULL
erythroblasts	NULL
and	NULL
erythropoietic	NULL
cell	NULL
lines	NULL
,	NULL
at	NULL
the	NULL
level	NULL
of	NULL
both	NULL
RNA	NULL
accumulation	NULL
and	NULL
protein	NULL
synthesis	NULL
,	NULL
whereas	NULL
it	NULL
was	NULL
significantly	NULL
lower	NULL
in	NULL
human	NULL
and	NULL
murine	NULL
Scal*	NULL
progenitors	NULL
and	NULL
virtually	NULL
absent	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
modified	NULL
LTR	NULL
appears	NULL
to	NULL
be	NULL
activated	NULL
in	NULL
cycling	NULL
progenitors	NULL
,	NULL
downregu-lated	NULL
in	NULL
myelo-monocytic	NULL
cells	NULL
,	NULL
and	NULL
maintained	NULL
at	NULL
sustained	NULL
levels	NULL
in	NULL
all	NULL
stages	NULL
of	NULL
erythroid	NULL
differentiation	NULL
,	NULL
strictly	NULL
paralleling	NULL
the	NULL
expression	NULL
pattern	NULL
of	NULL
the	NULL
GATA-1	NULL
gene	NULL
during	NULL
differentiation	NULL
of	NULL
human	NULL
primary	NULL
hematopoietic	NULL
cells	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
The	NULL
LTR	NULL
modification	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
integration	NULL
and	NULL
stability	NULL
of	NULL
the	NULL
provirus	NULL
in	NULL
the	NULL
target	NULL
cell	NULL
genome	NULL
.	NULL

Enhancer	NULL
replacement	NULL
is	NULL
therefore	NULL
an	NULL
effective	NULL
strategy	NULL
to	NULL
target	NULL
transcription	NULL
of	NULL
a	NULL
retroviral	NULL
genome	NULL
to	NULL
a	NULL
specific	NULL
progeny	NULL
of	NULL
stem	NULL
cells	NULL
transduced	NULL
ex	NULL
vivo	NULL
and	NULL
reintroduced	NULL
into	NULL
an	NULL
active	NULL
hematopoietic	NULL
system	NULL
.	NULL

These	NULL
data	NULL
provide	NULL
new	NULL
insight	NULL
into	NULL
the	NULL
role	NULL
of	NULL
the	NULL
ARE	NULL
in	NULL
the	NULL
physiological	NULL
regulation	NULL
of	NULL
the	NULL
GATA-1	NULL
gene	NULL
.	NULL

In	NULL
adult	NULL
mice	NULL
,	NULL
expression	NULL
of	NULL
GATA-1	NULL
is	NULL
restricted	NULL
to	NULL
hematopoietic	NULL
cells	NULL
and	NULL
Sertoli	NULL
cells	NULL
of	NULL
the	NULL
testis	NULL
by	NULL
the	NULL
activity	NULL
of	NULL
two	NULL
alternative	NULL
promoters	NULL
,	NULL
designated	NULL
IE	NULL
and	NULL
IT	NULL
,	NULL
located	NULL
approximately	NULL
8	NULL
kb	NULL
apart	NULL
on	NULL
the	NULL
X	NULL
chromosome	NULL
.	NULL
``	NULL

''	NULL
The	NULL
proximal	NULL
,	NULL
erythroid-specific	NULL
IE	NULL
promoter	NULL
drives	NULL
transcription	NULL
of	NULL
GATA-1	NULL
at	NULL
low	NULL
levels	NULL
in	NULL
multipotential	NULL
hematopoietic	NULL
progenitors	NULL
and	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
differentiating	NULL
erythroblasts	NULL
,	NULL
megacaryocytes	NULL
,	NULL
and	NULL
mast	NULL
cells	NULL
.	NULL
``	NULL

Initiation	NULL
and	NULL
maintenance	NULL
of	NULL
GATA-1	NULL
transcription	NULL
in	NULL
development	NULL
and	NULL
differentiation	NULL
of	NULL
both	NULL
primitive	NULL
and	NULL
definitive	NULL
erythropoietic	NULL
cells	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
under	NULL
the	NULL
control	NULL
of	NULL
multiple	NULL
,	NULL
DNase	NULL
hypersensitive	NULL
elements	NULL
located	NULL
upstream	NULL
(	NULL
from	NULL
-3,900	NULL
to	NULL
-2,700	NULL
)	NULL
and	NULL
downstream	NULL
(	NULL
first	NULL
intron	NULL
)	NULL
of	NULL
the	NULL
IE	NULL
pro-moter	NULL
.	NULL
``	NULL

The	NULL
ARE	NULL
(	NULL
-856	NULL
to	NULL
-655	NULL
from	NULL
the	NULL
IE	NULL
promoter	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
two	NULL
GATA-1	NULL
binding	NULL
sites	NULL
,	NULL
was	NULL
originally	NULL
identified	NULL
by	NULL
in	NULL
vitro	NULL
footprinting	NULL
``	NULL
and	NULL
shown	NULL
to	NULL
restrict	NULL
expression	NULL
of	NULL
a	NULL
heterologous	NULL
promoter	NULL
to	NULL
erythroblastic	NULL
cell	NULL
lines	NULL
in	NULL
a	NULL
transient	NULL
transfection	NULL
assay	NULL
.	NULL
'	NULL

''	NULL
8	NULL
Although	NULL
its	NULL
role	NULL
has	NULL
not	NULL
been	NULL
addressed	NULL
by	NULL
direct	NULL
mutagenesis	NULL
in	NULL
vivo	NULL
and	NULL
remains	NULL
therefore	NULL
uncertain	NULL
,	NULL
this	NULL
element	NULL
might	NULL
cooperate	NULL
in	NULL
erythroid-specific	NULL
maintenance	NULL
of	NULL
GATA-1	NULL
gene	NULL
expression	NULL
by	NULL
activating	NULL
a	NULL
GATA-1-driven	NULL
auto-regulatory	NULL
loop	NULL
.	NULL
'	NULL

''	NULL
``	NULL
*	NULL
Our	NULL
data	NULL
provide	NULL
the	NULL
first	NULL
in	NULL
vivo	NULL
evidence	NULL
for	NULL
such	NULL
a	NULL
role	NULL
by	NULL
showing	NULL
that	NULL
transcription	NULL
of	NULL
a	NULL
transgene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
GATA-1	NULL
ARE	NULL
is	NULL
activated	NULL
in	NULL
early	NULL
hematopoietic	NULL
progenitors	NULL
(	NULL
Scal+*	NULL
)	NULL
and	NULL
maintained	NULL
at	NULL
significant	NULL
levels	NULL
throughout	NULL
erythropoietic	NULL
differentiation	NULL
with	NULL
a	NULL
kinetics	NULL
virtually	NULL
overlapping	NULL
that	NULL
of	NULL
the	NULL
endogenous	NULL
GATA-1	NULL
gene	NULL
.	NULL

The	NULL
auto-regulatory	NULL
circuit	NULL
established	NULL
by	NULL
the	NULL
ARE	NULL
is	NULL
therefore	NULL
sufficient	NULL
to	NULL
maintain	NULL
GATA-1	NULL
3283	NULL
dependent	NULL
transcription	NULL
in	NULL
differentiating	NULL
erythroblasts	NULL
.	NULL

This	NULL
circuit	NULL
might	NULL
be	NULL
essential	NULL
to	NULL
sustain	NULL
GATA-1	NULL
transcription	NULL
at	NULL
appropriate	NULL
levels	NULL
in	NULL
erythroid	NULL
cells	NULL
,	NULL
the	NULL
maturation	NULL
of	NULL
which	NULL
is	NULL
dose-dependent	NULL
with	NULL
respect	NULL
to	NULL
GATA-1	NULL
levels	NULL
.	NULL
``	NULL

''	NULL
As	NULL
a	NULL
strategy	NULL
for	NULL
transcriptional	NULL
targeting	NULL
,	NULL
manipulating	NULL
the	NULL
LTR	NULL
control	NULL
elements	NULL
offers	NULL
a	NULL
number	NULL
of	NULL
advantages	NULL
.	NULL

First	NULL
,	NULL
it	NULL
provides	NULL
a	NULL
more	NULL
efficient	NULL
vector	NULL
design	NULL
,	NULL
which	NULL
allows	NULL
us	NULL
to	NULL
use	NULL
the	NULL
major	NULL
viral	NULL
transcription	NULL
unit	NULL
to	NULL
express	NULL
the	NULL
gene	NULL
of	NULL
interest	NULL
under	NULL
the	NULL
form	NULL
of	NULL
a	NULL
spliceable	NULL
RNA	NULL
.	NULL

Second	NULL
,	NULL
it	NULL
allows	NULL
the	NULL
use	NULL
of	NULL
a	NULL
second	NULL
,	NULL
independently	NULL
regulated	NULL
internal	NULL
promoter	NULL
to	NULL
control	NULL
an	NULL
additional	NULL
function	NULL
,	NULL
such	NULL
as	NULL
a	NULL
positive	NULL
(	NULL
NeoR	NULL
or	NULL
ALNGFR	NULL
)	NULL
or	NULL
negative	NULL
(	NULL
HSV-TK	NULL
)	NULL
selectable	NULL
marker	NULL
for	NULL
selecting	NULL
packaging	NULL
cells	NULL
or	NULL
eliminating	NULL
transduced	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Third	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
genomic	NULL
control	NULL
element	NULL
into	NULL
the	NULL
LTR	NULL
could	NULL
reduce	NULL
the	NULL
chances	NULL
of	NULL
chromatin-mediated	NULL
inactivation	NULL
of	NULL
the	NULL
integrated	NULL
provirus	NULL
.	NULL

This	NULL
is	NULL
known	NULL
to	NULL
affect	NULL
the	NULL
long-term	NULL
maintenance	NULL
of	NULL
MoMLV	NULL
LTR-driven	NULL
gene	NULL
expression	NULL
particularly	NULL
in	NULL
stem	NULL
cells	NULL
``	NULL
``	NULL
and	NULL
has	NULL
been	NULL
circumvented	NULL
in	NULL
the	NULL
past	NULL
by	NULL
replacing	NULL
the	NULL
MoMLV	NULL
enhancer	NULL
with	NULL
that	NULL
of	NULL
viruses	NULL
with	NULL
different	NULL
tropism	NULL
.	NULL

``	NULL
Â°4	NULL
'	NULL
The	NULL
use	NULL
of	NULL
genomic	NULL
instead	NULL
of	NULL
viral	NULL
sequences	NULL
could	NULL
have	NULL
the	NULL
additional	NULL
advantage	NULL
of	NULL
promoting	NULL
transcriptionally	NULL
active	NULL
chromatin	NULL
configurations	NULL
only	NULL
in	NULL
the	NULL
cells	NULL
in	NULL
which	NULL
the	NULL
transgene	NULL
is	NULL
transcriptionally	NULL
targeted	NULL
.	NULL

We	NULL
had	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
simple	NULL
insertion	NULL
of	NULL
a	NULL
muscle-specific	NULL
enhancer	NULL
into	NULL
an	NULL
intact	NULL
MoMLV	NULL
LTR	NULL
is	NULL
sufficient	NULL
to	NULL
restrict	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
viral	NULL
promoter	NULL
to	NULL
differentiated	NULL
muscle	NULL
fibers	NULL
.	NULL
``	NULL

However	NULL
,	NULL
the	NULL
same	NULL
design	NULL
was	NULL
unsuccessful	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
GATA-1	NULL
ARE	NULL
,	NULL
which	NULL
has	NULL
no	NULL
effect	NULL
in	NULL
modulating	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
LTR	NULL
if	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
viral	NULL
enhancer	NULL
(	NULL
G.F.	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Replacing	NULL
,	NULL
rather	NULL
than	NULL
adding	NULL
sequences	NULL
to	NULL
,	NULL
the	NULL
viral	NULL
enhancer	NULL
therefore	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
more	NULL
efficient	NULL
strategy	NULL
to	NULL
restrict	NULL
transcriptional	NULL
activity	NULL
of	NULL
retroviral	NULL
vectors	NULL
,	NULL
although	NULL
its	NULL
general	NULL
applicability	NULL
needs	NULL
to	NULL
be	NULL
tested	NULL
in	NULL
additional	NULL
contexts	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
LTR	NULL
architecture	NULL
imposes	NULL
a	NULL
number	NULL
of	NULL
constrains	NULL
upon	NULL
the	NULL
elements	NULL
that	NULL
it	NULL
can	NULL
accommodate	NULL
,	NULL
such	NULL
as	NULL
the	NULL
distance	NULL
between	NULL
the	NULL
enhancer	NULL
and	NULL
the	NULL
promoter	NULL
and	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
enhancer	NULL
itself	NULL
,	NULL
and	NULL
it	NULL
is	NULL
reasonable	NULL
to	NULL
assume	NULL
that	NULL
some	NULL
tissue-or	NULL
cell-specific	NULL
elements	NULL
could	NULL
be	NULL
unable	NULL
to	NULL
drive	NULL
the	NULL
TATA-containing	NULL
LTR	NULL
promoter	NULL
in	NULL
an	NULL
appropriate	NULL
fashion	NULL
.	NULL

Unpredictable	NULL
behavior	NULL
of	NULL
chimeric	NULL
LTRs	NULL
has	NULL
already	NULL
been	NULL
observed	NULL
in	NULL
the	NULL
past	NULL
.	NULL
``	NULL

Maintaining	NULL
the	NULL
LTR	NULL
CAAT	NULL
element	NULL
downstream	NULL
from	NULL
the	NULL
replaced	NULL
enhancer	NULL
increases	NULL
the	NULL
transcriptional	NULL
efficiency	NULL
of	NULL
the	NULL
chimeric	NULL
LTR	NULL
by	NULL
increasing	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
basal	NULL
promoter	NULL
,	NULL
although	NULL
this	NULL
necessarily	NULL
limits	NULL
the	NULL
stringency	NULL
of	NULL
the	NULL
tissue-	NULL
or	NULL
cell	NULL
lineage-specificity'*	NULL
(	NULL
see	NULL
Results	NULL
)	NULL
.	NULL

The	NULL
overall	NULL
size	NULL
of	NULL
the	NULL
inserted	NULL
fragment	NULL
can	NULL
also	NULL
be	NULL
a	NULL
problem	NULL
:	NULL
an	NULL
LTR	NULL
much	NULL
bigger	NULL
than	NULL
its	NULL
normal	NULL
size	NULL
reduces	NULL
both	NULL
viral	NULL
titer	NULL
and	NULL
stability	NULL
of	NULL
proviral	NULL
integration	NULL
,	NULL
most	NULL
likely	NULL
because	NULL
of	NULL
decreased	NULL
efficiency	NULL
of	NULL
reverse	NULL
Although	NULL
titer	NULL
problems	NULL
could	NULL
be	NULL
overcome	NULL
in	NULL
a	NULL
number	NULL
of	NULL
ways	NULL
,	NULL
a	NULL
high	NULL
frequency	NULL
of	NULL
rearrangement	NULL
would	NULL
limit	NULL
the	NULL
practical	NULL
use	NULL
of	NULL
certain	NULL
enhancer-replaced	NULL
vectors	NULL
.	NULL

The	NULL
vector	NULL
targeting	NULL
strategy	NULL
described	NULL
in	NULL
this	NULL
paper	NULL
could	NULL
be	NULL
potentially	NULL
relevant	NULL
for	NULL
gene	NULL
therapy	NULL
of	NULL
hemoglobinopathies	NULL
.	NULL

Current	NULL
attempts	NULL
to	NULL
build	NULL
retroviral	NULL
vectors	NULL
for	NULL
expression	NULL
of	NULL
B-globin	NULL
in	NULL
erythropoietic	NULL
cells	NULL
are	NULL
based	NULL
on	NULL
the	NULL
use	NULL
of	NULL
a	NULL
full	NULL
B-globin	NULL
gene	NULL
and	NULL
part	NULL
of	NULL
the	NULL
-globin	NULL
locus	NULL
control	NULL
region	NULL
(	NULL
LCR	NULL
)	NULL
,	NULL
with	NULL
the	NULL
rationale	NULL
of	NULL
reproducing	NULL
,	NULL
on	NULL
a	NULL
smaller	NULL
size	NULL
3284	NULL
scale	NULL
,	NULL
the	NULL
high-level	NULL
and	NULL
position-independent	NULL
expression	NULL
provided	NULL
by	NULL
the	NULL
interaction	NULL
between	NULL
the	NULL
LCR	NULL
and	NULL
the	NULL
-globin	NULL
promoter	NULL
.	NULL

``	NULL
``	NULL
``	NULL
Â°	NULL
However	NULL
,	NULL
genetic	NULL
instability	NULL
severely	NULL
limits	NULL
the	NULL
possibility	NULL
of	NULL
using	NULL
full-length	NULL
LCR	NULL
sequences	NULL
in	NULL
the	NULL
context	NULL
of	NULL
a	NULL
retroviral	NULL
vector	NULL
,	NULL
``	NULL
``	NULL
``	NULL
``	NULL
whereas	NULL
small	NULL
LCR	NULL
fragments	NULL
are	NULL
apparently	NULL
unable	NULL
to	NULL
reduce	NULL
the	NULL
integration-dependent	NULL
variability	NULL
of	NULL
transgene	NULL
expression	NULL
observed	NULL
with	NULL
MoMLV-based	NULL
vectors	NULL
.	NULL
``	NULL

Indeed	NULL
,	NULL
the	NULL
very	NULL
concept	NULL
that	NULL
the	NULL
LCR	NULL
has	NULL
a	NULL
role	NULL
in	NULL
maintaining	NULL
an	NULL
open	NULL
chromatin	NULL
structure	NULL
to	NULL
the	NULL
globin	NULL
locus	NULL
has	NULL
been	NULL
challenged	NULL
by	NULL
more	NULL
recent	NULL
evidence	NULL
.	NULL
``	NULL

''	NULL
``	NULL
'	NULL
Binding	NULL
of	NULL
erythroid-specific	NULL
transcription	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
GATA-1	NULL
,	NULL
to	NULL
enhancers	NULL
of	NULL
erythroid-specific	NULL
genes	NULL
early	NULL
in	NULL
development	NULL
or	NULL
differentiation	NULL
could	NULL
instead	NULL
be	NULL
a	NULL
key	NULL
factor	NULL
in	NULL
initiation	NULL
and	NULL
maintenance	NULL
of	NULL
open	NULL
chromatin	NULL
configurations	NULL
.	NULL
``	NULL

Although	NULL
our	NULL
experiments	NULL
do	NULL
not	NULL
directly	NULL
address	NULL
this	NULL
issue	NULL
,	NULL
LTRs	NULL
engineered	NULL
with	NULL
GATA-1-responsive	NULL
elements	NULL
could	NULL
therefore	NULL
provide	NULL
a	NULL
certain	NULL
degree	NULL
of	NULL
position-independence	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
integrated	NULL
proviruses	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

A	NULL
potential	NULL
limitation	NULL
of	NULL
such	NULL
a	NULL
vector	NULL
design	NULL
could	NULL
be	NULL
an	NULL
insufficient	NULL
level	NULL
of	NULL
B-globin	NULL
mRNA	NULL
accumulation	NULL
,	NULL
which	NULL
even	NULL
in	NULL
the	NULL
best	NULL
conditions	NULL
(	NULL
use	NULL
of	NULL
a	NULL
B-globin	NULL
promoter	NULL
and	NULL
noncoding	NULL
trailer	NULL
sequences	NULL
)	NULL
,	NULL
is	NULL
likely	NULL
to	NULL
remain	NULL
lower	NULL
than	NULL
that	NULL
obtainable	NULL
with	NULL
an	NULL
LCR	NULL
.	NULL

However	NULL
,	NULL
even	NULL
a	NULL
mild	NULL
correction	NULL
of	NULL
the	NULL
B-globin	NULL
imbalance	NULL
in	NULL
maturing	NULL
erythroblasts	NULL
might	NULL
be	NULL
sufficient	NULL
to	NULL
reduce	NULL
ineffective	NULL
erythropoiesis	NULL
in	NULL
severe	NULL
B-thalassemia	NULL
pa-tients	NULL
``	NULL
and	NULL
significantly	NULL
affect	NULL
both	NULL
morbidity	NULL
and	NULL
clinical	NULL
management	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

On	NULL
the	NULL
short-term	NULL
,	NULL
a	NULL
limited-correction	NULL
gene	NULL
therapy	NULL
strategy	NULL
based	NULL
on	NULL
autologous	NULL
transplantation	NULL
of	NULL
BM	NULL
transduced	NULL
with	NULL
a	NULL
transcriptionally	NULL
targeted	NULL
retroviral	NULL
vector	NULL
could	NULL
therefore	NULL
be	NULL
a	NULL
safe	NULL
and	NULL
viable	NULL
alternative	NULL
to	NULL
a	NULL
still	NULL
elusive	NULL
full	NULL
functional	NULL
replacement	NULL
of	NULL
the	NULL
-globin	NULL
locus	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
thank	NULL
C.	NULL
Moroni	NULL
for	NULL
the	NULL
initial	NULL
help	NULL
in	NULL
constructing	NULL
and	NULL
testing	NULL
hybrid	NULL
LTRs	NULL
and	NULL
G.	NULL
Torriani	NULL
and	NULL
R.	NULL
Parma	NULL
for	NULL
the	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Mulligan	NULL
RC	NULL
:	NULL
The	NULL
basic	NULL
science	NULL
of	NULL
gene	NULL
therapy	NULL
.	NULL

Science	NULL
260:926	NULL
,	NULL
1993	NULL
2	NULL
.	NULL

Crystal	NULL
RG	NULL
:	NULL
Transfer	NULL
of	NULL
genes	NULL
to	NULL
humans	NULL
:	NULL
Early	NULL
lessons	NULL
and	NULL
obstacles	NULL
to	NULL
success	NULL
.	NULL

Science	NULL
270:404	NULL
,	NULL
1995	NULL
3	NULL
.	NULL

Verma	NULL
IM	NULL
,	NULL
Somia	NULL
N	NULL
:	NULL
Gene	NULL
therapy-Promises	NULL
,	NULL
problems	NULL
and	NULL
prospects	NULL
.	NULL

Nature	NULL
389:239	NULL
,	NULL
1997	NULL
4	NULL
.	NULL

Emerman	NULL
M	NULL
,	NULL
Temin	NULL
HM	NULL
:	NULL
Genes	NULL
with	NULL
promoters	NULL
in	NULL
retrovirus	NULL
vectors	NULL
can	NULL
be	NULL
independently	NULL
suppressed	NULL
by	NULL
an	NULL
epigenetic	NULL
mechanism	NULL
.	NULL

Cell	NULL
39:449	NULL
,	NULL
1984	NULL
5	NULL
.	NULL

Emerman	NULL
M	NULL
,	NULL
Temin	NULL
HM	NULL
:	NULL
Quantitative	NULL
analysis	NULL
of	NULL
gene	NULL
suppression	NULL
in	NULL
integrated	NULL
retrovirus	NULL
vectors	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
6:792	NULL
,	NULL
1986	NULL
6	NULL
.	NULL

Miller	NULL
N	NULL
,	NULL
Whelan	NULL
J	NULL
:	NULL
Progress	NULL
in	NULL
transcriptionally	NULL
targeted	NULL
and	NULL
regulatable	NULL
vectors	NULL
for	NULL
genetic	NULL
therapy	NULL
.	NULL

Hum	NULL
Gene	NULL
Ther	NULL
8:803	NULL
,	NULL
1997	NULL
7	NULL
.	NULL

Yu	NULL
S	NULL
,	NULL
von	NULL
Ruden	NULL
T	NULL
,	NULL
Kantoff	NULL
PW	NULL
,	NULL
Garber	NULL
C	NULL
,	NULL
Sciberg	NULL
M	NULL
,	NULL
Rather	NULL
U	NULL
,	NULL
Anderson	NULL
WF	NULL
,	NULL
Wagner	NULL
EF	NULL
,	NULL
Gilboa	NULL
E	NULL
:	NULL
Self-inactivating	NULL
retroviral	NULL
vectors	NULL
designed	NULL
for	NULL
transfer	NULL
of	NULL
whole	NULL
genes	NULL
into	NULL
mammalian	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
83:3194	NULL
,	NULL
1986	NULL
8	NULL
.	NULL

Yee	NULL
JK	NULL
,	NULL
Moores	NULL
JC	NULL
,	NULL
Jolly	NULL
DJ	NULL
,	NULL
Wolff	NULL
JA	NULL
,	NULL
Respess	NULL
JG	NULL
,	NULL
Friedmann	NULL
T	NULL
:	NULL
Gene	NULL
expression	NULL
from	NULL
transcriptionally	NULL
disabled	NULL
retroviral	NULL
vectors	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
84:5197	NULL
,	NULL
1987	NULL
9	NULL
.	NULL

Naffakh	NULL
N	NULL
,	NULL
Pinset	NULL
C	NULL
,	NULL
Montarras	NULL
D	NULL
,	NULL
Li	NULL
Z	NULL
,	NULL
Paulin	NULL
D	NULL
,	NULL
Danos	NULL
O	NULL
,	NULL
GRANDE	NULL
ET	NULL
AL	NULL
Heard	NULL
JM	NULL
:	NULL
Long-term	NULL
secretion	NULL
of	NULL
therapeutic	NULL
proteins	NULL
from	NULL
genetically	NULL
modified	NULL
skeletal	NULL
muscles	NULL
.	NULL

Hum	NULL
Gene	NULL
Ther	NULL
7:11	NULL
,	NULL
1996	NULL
10	NULL
.	NULL

Karlsson	NULL
S	NULL
,	NULL
Papayannopoulou	NULL
T	NULL
,	NULL
Schweiger	NULL
SG	NULL
,	NULL
Stamatoyannopoulos	NULL
G	NULL
,	NULL
Nienhuis	NULL
AW	NULL
:	NULL
Retroviral-mediated	NULL
transfer	NULL
of	NULL
genomic	NULL
globin	NULL
genes	NULL
leads	NULL
to	NULL
regulated	NULL
production	NULL
of	NULL
RNA	NULL
and	NULL
protein	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
84:2411	NULL
,	NULL
1987	NULL
11	NULL
.	NULL

Hantzopoulos	NULL
PA	NULL
,	NULL
Sullenger	NULL
BA	NULL
,	NULL
Ungers	NULL
G	NULL
,	NULL
Gilboa	NULL
E	NULL
:	NULL
Improved	NULL
gene	NULL
expression	NULL
upon	NULL
transfer	NULL
of	NULL
the	NULL
adenosine	NULL
deaminase	NULL
minigene	NULL
outside	NULL
the	NULL
transcriptional	NULL
unit	NULL
of	NULL
a	NULL
retroviral	NULL
vector	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86:3519	NULL
,	NULL
1989	NULL
12	NULL
.	NULL

Davis	NULL
B	NULL
,	NULL
Linney	NULL
E	NULL
,	NULL
Fan	NULL
H	NULL
:	NULL
Suppression	NULL
of	NULL
leukaemia	NULL
virus	NULL
pathogenicity	NULL
by	NULL
polyoma	NULL
virus	NULL
enhancers	NULL
.	NULL

Nature	NULL
314:550	NULL
,	NULL
1985	NULL
13	NULL
.	NULL

Ferrari	NULL
G	NULL
,	NULL
Salvatori	NULL
G	NULL
,	NULL
Rossi	NULL
C	NULL
,	NULL
Cossu	NULL
G	NULL
,	NULL
Mavilio	NULL
F	NULL
:	NULL
A	NULL
retroviral	NULL
vector	NULL
containing	NULL
a	NULL
muscle-specific	NULL
enhancer	NULL
drives	NULL
gene	NULL
expression	NULL
only	NULL
in	NULL
differentiated	NULL
muscle	NULL
fibers	NULL
.	NULL

Hum	NULL
Gene	NULL
Ther	NULL
6:733	NULL
,	NULL
1995	NULL
14	NULL
.	NULL

Diaz	NULL
RM	NULL
,	NULL
Eisen	NULL
T	NULL
,	NULL
Hart	NULL
IR	NULL
,	NULL
Vile	NULL
RG	NULL
:	NULL
Exchange	NULL
of	NULL
viral	NULL
promoter/enhancer	NULL
elements	NULL
with	NULL
heterologous	NULL
regulatory	NULL
sequences	NULL
generates	NULL
targeted	NULL
hybrid	NULL
long	NULL
terminal	NULL
repeat	NULL
vectors	NULL
for	NULL
gene	NULL
therapy	NULL
of	NULL
melanoma	NULL
.	NULL

J	NULL
Virol	NULL
72:789	NULL
,	NULL
1998	NULL
15	NULL
.	NULL

Tsai	NULL
SF	NULL
,	NULL
Martin	NULL
DI	NULL
,	NULL
Zon	NULL
LL	NULL
,	NULL
D'Andrea	NULL
AD	NULL
,	NULL
Wong	NULL
GG	NULL
,	NULL
Orkin	NULL
SH	NULL
:	NULL
Cloning	NULL
of	NULL
cDNA	NULL
for	NULL
the	NULL
major	NULL
DNA-binding	NULL
protein	NULL
of	NULL
the	NULL
erythroid	NULL
lineage	NULL
through	NULL
expression	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Nature	NULL
339:446	NULL
,	NULL
1989	NULL
16	NULL
.	NULL

Evans	NULL
T	NULL
,	NULL
Felsenfeld	NULL
G	NULL
:	NULL
The	NULL
erythroid-specific	NULL
transcription	NULL
factor	NULL
Eryf1	NULL
:	NULL
A	NULL
new	NULL
finger	NULL
protein	NULL
.	NULL

Cell	NULL
58:877	NULL
,	NULL
1989	NULL
17	NULL
.	NULL

Tsai	NULL
SF	NULL
,	NULL
Strauss	NULL
E	NULL
,	NULL
Orkin	NULL
SH	NULL
:	NULL
Functional	NULL
analysis	NULL
and	NULL
in	NULL
vivo	NULL
footprinting	NULL
implicate	NULL
the	NULL
erythroid	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
as	NULL
a	NULL
positive	NULL
regulator	NULL
of	NULL
its	NULL
own	NULL
promoter	NULL
.	NULL

Genes	NULL
Dev	NULL
5:919	NULL
,	NULL
1991	NULL
18	NULL
.	NULL

Nicolis	NULL
S	NULL
,	NULL
Bertini	NULL
C	NULL
,	NULL
Ronchi	NULL
A	NULL
,	NULL
Crotta	NULL
S	NULL
,	NULL
Lanfranco	NULL
L	NULL
,	NULL
Moroni	NULL
E	NULL
,	NULL
Giglioni	NULL
B	NULL
,	NULL
Ottolenghi	NULL
S	NULL
:	NULL
An	NULL
erythroid	NULL
specific	NULL
enhancer	NULL
upstream	NULL
to	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
cell-type	NULL
specific	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
19:5285	NULL
,	NULL
1991	NULL
19	NULL
.	NULL

Mavilio	NULL
F	NULL
,	NULL
Ferrari	NULL
G	NULL
,	NULL
Rossini	NULL
S	NULL
,	NULL
Nobili	NULL
N	NULL
,	NULL
Bonini	NULL
C	NULL
,	NULL
Casorati	NULL
G	NULL
,	NULL
Traversari	NULL
C	NULL
,	NULL
Bordignon	NULL
C	NULL
:	NULL
Peripheral	NULL
blood	NULL
lymphocytes	NULL
as	NULL
target	NULL
cells	NULL
of	NULL
retroviral	NULL
vector-mediated	NULL
gene	NULL
transfer	NULL
.	NULL

Blood	NULL
83:1988	NULL
,	NULL
1994	NULL
20	NULL
.	NULL

Ruggieri	NULL
L	NULL
,	NULL
Aiuti	NULL
A	NULL
,	NULL
Salomoni	NULL
M	NULL
,	NULL
Zappone	NULL
E	NULL
,	NULL
Ferrari	NULL
G	NULL
,	NULL
Bordignon	NULL
C	NULL
:	NULL
Cell-surface	NULL
marking	NULL
of	NULL
CD	NULL
(	NULL
34+	NULL
)	NULL
-restricted	NULL
phenotypes	NULL
of	NULL
human	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
by	NULL
retrovirus-mediated	NULL
gene	NULL
transfer	NULL
.	NULL

Hum	NULL
Gene	NULL
Ther	NULL
8:1611	NULL
,	NULL
1997	NULL
21	NULL
.	NULL

Miller	NULL
AD	NULL
,	NULL
Rosman	NULL
GJ	NULL
:	NULL
Improved	NULL
retroviral	NULL
vectors	NULL
for	NULL
gene	NULL
transfer	NULL
and	NULL
expression	NULL
.	NULL

Biotechniques	NULL
7:980	NULL
,	NULL
1989	NULL
22	NULL
.	NULL

Markowitz	NULL
D	NULL
,	NULL
Goff	NULL
S	NULL
,	NULL
Bank	NULL
A	NULL
:	NULL
A	NULL
safe	NULL
packaging	NULL
line	NULL
for	NULL
gene	NULL
transfer	NULL
:	NULL
Separating	NULL
viral	NULL
genes	NULL
on	NULL
two	NULL
different	NULL
plasmids	NULL
.	NULL

J	NULL
Virol	NULL
62:1120	NULL
,	NULL
1988	NULL
23	NULL
.	NULL

Markowitz	NULL
D	NULL
,	NULL
Goff	NULL
S	NULL
,	NULL
Bank	NULL
A	NULL
:	NULL
Construction	NULL
and	NULL
use	NULL
of	NULL
a	NULL
safe	NULL
and	NULL
efficient	NULL
amphotropic	NULL
packaging	NULL
cell	NULL
line	NULL
.	NULL

Virology	NULL
167:400	NULL
,	NULL
1988	NULL
24	NULL
.	NULL

Sadelain	NULL
M	NULL
,	NULL
Wang	NULL
CH	NULL
,	NULL
Antoniou	NULL
M	NULL
,	NULL
Grosveld	NULL
F	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Generation	NULL
of	NULL
a	NULL
high-titer	NULL
retroviral	NULL
vector	NULL
capable	NULL
of	NULL
expressing	NULL
high	NULL
levels	NULL
of	NULL
the	NULL
human	NULL
beta-globin	NULL
gene	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:6728	NULL
,	NULL
1995	NULL
25	NULL
.	NULL

Aiuti	NULL
A	NULL
,	NULL
Friedrich	NULL
C	NULL
,	NULL
Sieff	NULL
CA	NULL
,	NULL
Gutierrez-Ramos	NULL
JC	NULL
:	NULL
Identification	NULL
of	NULL
distinct	NULL
elements	NULL
of	NULL
the	NULL
stromal	NULL
microenvironment	NULL
that	NULL
control	NULL
human	NULL
hematopoietic	NULL
stem/progenitor	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

Exp	NULL
Hematol	NULL
26:143	NULL
,	NULL
1998	NULL
26	NULL
.	NULL

Catulo	NULL
A	NULL
,	NULL
Nicolis	NULL
S	NULL
,	NULL
Bianchi	NULL
P	NULL
,	NULL
Zuffardi	NULL
O	NULL
,	NULL
Bardoni	NULL
B	NULL
,	NULL
Maraschio	NULL
P	NULL
,	NULL
Ottolenghi	NULL
S	NULL
,	NULL
Camerino	NULL
G	NULL
,	NULL
Giglioni	NULL
B	NULL
:	NULL
Mapping	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
human	NULL
erythroid	NULL
transcription	NULL
factor	NULL
NFE1-GF1	NULL
to	NULL
Xp11.23	NULL
.	NULL

Hum	NULL
Genet	NULL
86:388	NULL
,	NULL
1991	NULL
27	NULL
.	NULL

Loken	NULL
MR	NULL
,	NULL
Shah	NULL
VO	NULL
,	NULL
Dattilio	NULL
KL	NULL
,	NULL
Civin	NULL
CI	NULL
:	NULL
Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
human	NULL
bone	NULL
marrow	NULL
:	NULL
I	NULL
.	NULL

Normal	NULL
erythroid	NULL
development	NULL
.	NULL

Blood	NULL
69:255	NULL
,	NULL
1987	NULL
28	NULL
.	NULL

Sposi	NULL
NM	NULL
,	NULL
Zon	NULL
LI	NULL
,	NULL
Care	NULL
A	NULL
,	NULL
Valtieri	NULL
M	NULL
,	NULL
Testa	NULL
U	NULL
,	NULL
Gabbianelli	NULL
M	NULL
,	NULL
Mariani	NULL
G	NULL
,	NULL
Bottero	NULL
L	NULL
,	NULL
Mather	NULL
C	NULL
,	NULL
Orkin	NULL
SH	NULL
,	NULL
Peschle	NULL
C	NULL
:	NULL
Cell	NULL
cycle-dependent	NULL
initiation	NULL
and	NULL
lineage-dependent	NULL
abrogation	NULL
of	NULL
GATA-1	NULL
expression	NULL
in	NULL
pure	NULL
differentiating	NULL
hematopoietic	NULL
progenitors	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:6353	NULL
,	NULL
1992	NULL
TRANSCRIPTIONAL	NULL
TARGETING	NULL
OF	NULL
RETROVIRAL	NULL
VECTORS	NULL
29	NULL
.	NULL

Cheng	NULL
T	NULL
,	NULL
Shen	NULL
H	NULL
,	NULL
Giokas	NULL
D	NULL
,	NULL
Gere	NULL
J	NULL
,	NULL
Tenen	NULL
DG	NULL
,	NULL
Scadden	NULL
DT	NULL
:	NULL
Temporal	NULL
mapping	NULL
of	NULL
gene	NULL
expression	NULL
levels	NULL
during	NULL
the	NULL
differentiation	NULL
of	NULL
individual	NULL
primary	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
93:13158	NULL
,	NULL
1996	NULL
30	NULL
.	NULL

Ito	NULL
E	NULL
,	NULL
Toki	NULL
T	NULL
,	NULL
Ishihara	NULL
H	NULL
,	NULL
Ohtani	NULL
H	NULL
,	NULL
Gu	NULL
L	NULL
,	NULL
Yokoyama	NULL
M	NULL
,	NULL
Engel	NULL
JD	NULL
,	NULL
Yamamoto	NULL
M	NULL
:	NULL
Erythroid	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
is	NULL
abundantly	NULL
transcribed	NULL
in	NULL
mouse	NULL
testis	NULL
.	NULL

Nature	NULL
362:466	NULL
,	NULL
1993	NULL
31	NULL
.	NULL

Orkin	NULL
SH	NULL
:	NULL
GATA-binding	NULL
transcription	NULL
factors	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Blood	NULL
80:575	NULL
,	NULL
1992	NULL
32	NULL
.	NULL

Onodera	NULL
K	NULL
,	NULL
Takahashi	NULL
S	NULL
,	NULL
Nishimura	NULL
S	NULL
,	NULL
Ohta	NULL
J	NULL
,	NULL
Motohashi	NULL
H	NULL
,	NULL
Yomogida	NULL
K	NULL
,	NULL
Hayashi	NULL
N	NULL
,	NULL
Engel	NULL
JD	NULL
,	NULL
Yamamoto	NULL
M	NULL
:	NULL
GATA-1	NULL
transcription	NULL
is	NULL
controlled	NULL
by	NULL
distinct	NULL
regulatory	NULL
mechanisms	NULL
during	NULL
primitive	NULL
and	NULL
definitive	NULL
erythropoiesis	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
94:4487	NULL
,	NULL
1997	NULL
33	NULL
.	NULL

McDevitt	NULL
MA	NULL
,	NULL
Shivdasani	NULL
RA	NULL
,	NULL
Fujiwara	NULL
Y	NULL
,	NULL
Yang	NULL
H	NULL
,	NULL
Orkin	NULL
SH	NULL
:	NULL
A	NULL
``	NULL
knockdown	NULL
``	NULL
mutation	NULL
created	NULL
by	NULL
cis-element	NULL
gene	NULL
targeting	NULL
reveals	NULL
the	NULL
dependence	NULL
of	NULL
erythroid	NULL
cell	NULL
maturation	NULL
on	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
94:6781	NULL
,	NULL
1997	NULL
34	NULL
.	NULL

McDevitt	NULL
MA	NULL
,	NULL
Fujiwara	NULL
Y	NULL
,	NULL
Shivdasani	NULL
RA	NULL
,	NULL
Orkin	NULL
SH	NULL
:	NULL
An	NULL
upstream	NULL
,	NULL
DNase	NULL
I	NULL
hypersensitive	NULL
region	NULL
of	NULL
the	NULL
hematopoictic-expressed	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
gene	NULL
confers	NULL
developmental	NULL
specificity	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
94:7976	NULL
,	NULL
1997	NULL
35	NULL
.	NULL

Shivdasani	NULL
RA	NULL
,	NULL
Fujiwara	NULL
Y	NULL
,	NULL
McDevitt	NULL
MA	NULL
,	NULL
Orkin	NULL
SH	NULL
:	NULL
A	NULL
lineage-selective	NULL
knock-out	NULL
establishes	NULL
the	NULL
critical	NULL
role	NULL
of	NULL
transcription	NULL
factor	NULL
GATA-1	NULL
in	NULL
megacaryocyte	NULL
growth	NULL
and	NULL
platelet	NULL
development	NULL
.	NULL

EMBO	NULL
J	NULL
16:3965	NULL
,	NULL
1997	NULL
36	NULL
.	NULL

Palmer	NULL
TD	NULL
,	NULL
Rosman	NULL
GJ	NULL
,	NULL
Osborne	NULL
WRA	NULL
,	NULL
Miller	NULL
AD	NULL
:	NULL
Genetically	NULL
modified	NULL
skin	NULL
fibroblasts	NULL
persist	NULL
long	NULL
after	NULL
trasplantation	NULL
but	NULL
gradually	NULL
inactivate	NULL
introduced	NULL
genes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
88:1330	NULL
,	NULL
1991	NULL
37	NULL
.	NULL

Gerrard	NULL
AJ	NULL
,	NULL
Hudson	NULL
DL	NULL
,	NULL
Brownlee	NULL
GG	NULL
,	NULL
Watt	NULL
FM	NULL
:	NULL
Towards	NULL
gene	NULL
therapy	NULL
for	NULL
haemophilia	NULL
B	NULL
using	NULL
primary	NULL
human	NULL
keratinocytes	NULL
.	NULL

Nat	NULL
Genet	NULL
3:180	NULL
,	NULL
1993	NULL
38	NULL
.	NULL

Challita	NULL
PM	NULL
,	NULL
Kohn	NULL
DB	NULL
:	NULL
Lack	NULL
of	NULL
expression	NULL
from	NULL
a	NULL
retroviral	NULL
vector	NULL
after	NULL
transduction	NULL
of	NULL
murine	NULL
hematopoietic	NULL
stem	NULL
cells	NULL
is	NULL
associated	NULL
with	NULL
methylation	NULL
in	NULL
vivo	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
91:2567	NULL
,	NULL
1994	NULL
39.	NULL
van	NULL
Beusechem	NULL
VW	NULL
,	NULL
Kukler	NULL
A	NULL
,	NULL
Einerhand	NULL
MPW	NULL
,	NULL
Bakx	NULL
TA	NULL
,	NULL
van	NULL
der	NULL
Eb	NULL
AJ	NULL
,	NULL
Van	NULL
Bekkum	NULL
DW	NULL
,	NULL
Valerio	NULL
D	NULL
:	NULL
Expression	NULL
of	NULL
human	NULL
adenosine	NULL
deaminase	NULL
in	NULL
mice	NULL
transplanted	NULL
with	NULL
hemopoietic	NULL
stem	NULL
cells	NULL
infected	NULL
with	NULL
amphotropic	NULL
retroviruses	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
172:729	NULL
,	NULL
1990	NULL
40.	NULL
van	NULL
Beusechem	NULL
VW	NULL
,	NULL
Kukler	NULL
A	NULL
,	NULL
Heidt	NULL
PJ	NULL
,	NULL
Valerio	NULL
D	NULL
:	NULL
Long-term	NULL
expression	NULL
of	NULL
human	NULL
adenosine	NULL
deaminase	NULL
in	NULL
rhesus	NULL
monkeys	NULL
transplanted	NULL
with	NULL
retrovirus-infected	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:7640	NULL
,	NULL
1992	NULL
41	NULL
.	NULL

Riviere	NULL
I	NULL
,	NULL
Brose	NULL
K	NULL
,	NULL
Mulligan	NULL
RC	NULL
:	NULL
Effects	NULL
of	NULL
retroviral	NULL
vector	NULL
design	NULL
on	NULL
expression	NULL
of	NULL
human	NULL
adenosine	NULL
deaminase	NULL
in	NULL
murine	NULL
bone	NULL
marrow	NULL
transplant	NULL
recipients	NULL
engrafted	NULL
with	NULL
genetically	NULL
modified	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:6733	NULL
,	NULL
1995	NULL
3285	NULL
42	NULL
.	NULL

Kaptein	NULL
LC	NULL
,	NULL
Breuer	NULL
M	NULL
,	NULL
Valerio	NULL
D	NULL
,	NULL
van	NULL
Beusechem	NULL
VW	NULL
:	NULL
Expression	NULL
pattern	NULL
of	NULL
CD2	NULL
locus	NULL
control	NULL
region	NULL
containing	NULL
retroviral	NULL
vectors	NULL
in	NULL
hemopoietic	NULL
cells	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

Gene	NULL
Ther	NULL
5:320	NULL
,	NULL
1998	NULL
43	NULL
.	NULL

Ferrari	NULL
G	NULL
,	NULL
Rossini	NULL
S	NULL
,	NULL
Nobili	NULL
N	NULL
,	NULL
Maggioni	NULL
D	NULL
,	NULL
Garofalo	NULL
A	NULL
,	NULL
Giavazzi	NULL
R	NULL
,	NULL
Mavilio	NULL
F	NULL
,	NULL
Bordignon	NULL
C	NULL
:	NULL
Transfer	NULL
of	NULL
the	NULL
ADA	NULL
gene	NULL
into	NULL
human	NULL
ADA-deficient	NULL
T-lymphocytes	NULL
reconstitutes	NULL
specific	NULL
immune	NULL
function	NULL
.	NULL

Blood	NULL
80:1120	NULL
,	NULL
1992	NULL
44	NULL
.	NULL

Bordignon	NULL
C	NULL
,	NULL
Notarangelo	NULL
LD	NULL
,	NULL
Nobili	NULL
N	NULL
,	NULL
Ferrari	NULL
G	NULL
,	NULL
Casorati	NULL
G	NULL
,	NULL
Panina	NULL
P	NULL
,	NULL
Mazzolari	NULL
E	NULL
,	NULL
Maggioni	NULL
D	NULL
,	NULL
Rossi	NULL
C	NULL
,	NULL
Servida	NULL
P	NULL
,	NULL
Ugazio	NULL
AG	NULL
,	NULL
Mavilio	NULL
F	NULL
:	NULL
Gene	NULL
therapy	NULL
in	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
and	NULL
bone	NULL
marrow	NULL
for	NULL
ADA~	NULL
immunodeficient	NULL
patients	NULL
.	NULL

Science	NULL
270:470	NULL
,	NULL
1995	NULL
45	NULL
.	NULL

Beuzard	NULL
Y	NULL
:	NULL
Towards	NULL
gene	NULL
therapy	NULL
of	NULL
hemoglobinopathies	NULL
.	NULL

Semin	NULL
Hematol	NULL
33:43	NULL
,	NULL
1996	NULL
46	NULL
.	NULL

Ioannou	NULL
P	NULL
:	NULL
Gene	NULL
therapy	NULL
for	NULL
thalassaemia	NULL
.	NULL

Gene	NULL
Ther	NULL
3:746	NULL
,	NULL
1996	NULL
47	NULL
.	NULL

Novak	NULL
U	NULL
,	NULL
Harris	NULL
EA	NULL
,	NULL
Forrester	NULL
W	NULL
,	NULL
Groudine	NULL
M	NULL
,	NULL
Gelinas	NULL
R	NULL
:	NULL
High-level	NULL
beta-globin	NULL
expression	NULL
after	NULL
retroviral	NULL
transfer	NULL
of	NULL
locus	NULL
activation	NULL
region-containing	NULL
human	NULL
beta-globin	NULL
gene	NULL
derivatives	NULL
into	NULL
murine	NULL
erythroleukemia	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
87:3386	NULL
,	NULL
1990	NULL
48	NULL
.	NULL

Leboulch	NULL
P	NULL
,	NULL
Huang	NULL
GM	NULL
,	NULL
Humphries	NULL
RK	NULL
,	NULL
Oh	NULL
YH	NULL
,	NULL
Eaves	NULL
CJ	NULL
,	NULL
Tuan	NULL
DY	NULL
,	NULL
London	NULL
IM	NULL
:	NULL
Mutagenesis	NULL
of	NULL
retroviral	NULL
vectors	NULL
transducing	NULL
human	NULL
beta-globin	NULL
gene	NULL
and	NULL
beta-globin	NULL
locus	NULL
control	NULL
region	NULL
derivatives	NULL
results	NULL
in	NULL
stable	NULL
transmission	NULL
of	NULL
an	NULL
active	NULL
transcriptional	NULL
structure	NULL
.	NULL

EMBO	NULL
J	NULL
13:3065	NULL
,	NULL
1994	NULL
49	NULL
.	NULL

Raftopoulos	NULL
H	NULL
,	NULL
Ward	NULL
M	NULL
,	NULL
Leboulch	NULL
P	NULL
,	NULL
Bank	NULL
A	NULL
:	NULL
Long-term	NULL
transfer	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
B-globin	NULL
gene	NULL
in	NULL
a	NULL
mouse	NULL
transplant	NULL
model	NULL
.	NULL

Blood	NULL
90:3414	NULL
,	NULL
1997	NULL
50	NULL
.	NULL

Reik	NULL
A	NULL
,	NULL
Telling	NULL
A	NULL
,	NULL
Zitnik	NULL
G	NULL
,	NULL
Cimbora	NULL
D	NULL
,	NULL
Epner	NULL
E	NULL
,	NULL
Groudine	NULL
M	NULL
:	NULL
The	NULL
locus	NULL
control	NULL
region	NULL
is	NULL
necessary	NULL
for	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
human	NULL
B-globin	NULL
locus	NULL
but	NULL
not	NULL
the	NULL
maintainance	NULL
of	NULL
an	NULL
open	NULL
chromatin	NULL
structure	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
18:5992	NULL
,	NULL
1998	NULL
51	NULL
.	NULL

Epner	NULL
E	NULL
,	NULL
Reik	NULL
A	NULL
,	NULL
Cimbora	NULL
D	NULL
,	NULL
Telling	NULL
A	NULL
,	NULL
Bender	NULL
MA	NULL
,	NULL
Fiering	NULL
S	NULL
,	NULL
Enver	NULL
T	NULL
,	NULL
Martin	NULL
DIK	NULL
,	NULL
Kennedy	NULL
M	NULL
,	NULL
Keller	NULL
G	NULL
,	NULL
Groudine	NULL
M	NULL
:	NULL
The	NULL
B-globin	NULL
LCR	NULL
is	NULL
not	NULL
necessary	NULL
for	NULL
an	NULL
open	NULL
chromatin	NULL
structure	NULL
or	NULL
developmen-tally	NULL
regulated	NULL
transcription	NULL
of	NULL
the	NULL
native	NULL
mouse	NULL
B-globin	NULL
locus	NULL
.	NULL

Mol	NULL
Cell	NULL
2:447	NULL
,	NULL
1998	NULL
52	NULL
.	NULL

Orkin	NULL
SH	NULL
:	NULL
Regulation	NULL
of	NULL
globin	NULL
gene	NULL
expression	NULL
in	NULL
erythroid	NULL
cells	NULL
.	NULL

Eur	NULL
J	NULL
Biochem	NULL
231:271	NULL
,	NULL
1995	NULL
53	NULL
.	NULL

Martin	NULL
DI	NULL
,	NULL
Fiering	NULL
S	NULL
,	NULL
Groudine	NULL
M	NULL
:	NULL
Regulation	NULL
of	NULL
beta-globin	NULL
gene	NULL
expression	NULL
:	NULL
Straightening	NULL
out	NULL
the	NULL
locus	NULL
.	NULL

Curr	NULL
Opin	NULL
Gen	NULL
Dev	NULL
6:488	NULL
,	NULL
1996	NULL
54	NULL
.	NULL

Weatherall	NULL
DJ	NULL
:	NULL
The	NULL
thalassemias	NULL
,	NULL
in	NULL
Stamatoyannopoulos	NULL
G	NULL
,	NULL
Nienhuis	NULL
AW	NULL
,	NULL
Majerus	NULL
PW	NULL
,	NULL
Varmus	NULL
H	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
The	NULL
Molecular	NULL
Basis	NULL
of	NULL
Blood	NULL
Diseases	NULL
(	NULL
ed	NULL
2	NULL
)	NULL
.	NULL

Philadelphia	NULL
,	NULL
PA	NULL
,	NULL
Saunders	NULL
,	NULL
1994	NULL
,	NULL
p	NULL
157	NULL

